General References


Paakkari I. Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 2002; 127:279-84.

Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53:235-9.

Paatero I, Elenius K. ErbB4 and its isoforms: patentable drug targets? Recent Pat DNA Gene Seq 2008; 2:27-33.

Paavonen KJ, Swan H, Piippo K et al. Beta1-adrenergic receptor polymorphisms, QTc interval and occurrence of symptoms in type 1 of long QT syndrome. Int J Cardiol 2007; 118:197-202.

Pabarcus MK, Hoe N, Sadeghi S, Patterson C, Wiertz E, Correia MA. CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch Biochem Biophys 2009; 483:66-74.

Pabst S, Karpushova A, Diaz-Lacava A et al. VEGF gene haplotypes are associated with sarcoidosis. Chest 2010; 137:156-63.

Pacanowski MA, Gong Y, Cooper-Dehoff RM et al. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008; 84:715-21.

Pacanowski MA, Zineh I, Li H et al. Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation. J Transl Med 2008; 6:11.

Pacifici GM. Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature. Int J Clin Pharmacol Ther 2004; 42:488-95.

Paczkowska A, Szperl M, Małek Ł et al. Polymorphisms of the beta-1 and beta-2 adrenergic receptors in Polish patients with idiopathic dilated cardiomyopathy. Kardiol Pol 2009; 67:235-41.

Paczkowski FA, Bönisch H, Bryan-Lluka LJ. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter. Pharmacogenetics 2002; 12:165-73.

Pacheco AG, Cardoso CC, Moraes MO. IFNG +874T/A, IL10 -1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum Gene 2008; 123:477-84.

Pacheco CD, Elrick MJ, Lieberman AP. Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Hum Mol Genet 2009; 18:956-65.

Paddock S, Laje G, Charney D et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007; 164:1181-8.

Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet 2009; 48:303-11.

Padovani AM, Molina MF, Mann KK. Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol 2010; 30:1228-36.

Padowski JM, Pollack GM. Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein. J Pharm Sci 2010; 99:3226-33.

Padró-Miquel A, Alía-Ramos P, González-Alvarez MT, Navarro-Moreno MA. Survival in type 2 diabetic patients in dialysis and the number of risk alleles in polymorphisms of the renin-angiotensin system genes. Clin Biochem 2009; 42:5-11.

Pae CU, Drago A, Kim JJ, Mandelli L, de Ronchi D, Serretti A. The impact of heat shock protein 70 gene variations on clinical presentation and outcome in schizophrenic inpatients. Neuropsychobiology 2009; 59:135-41.

Pae CU, Mandelli L, de Ronchi D et al. Dysbindin gene (DTNBP1) and schizophrenia in Korean population. Eur Arch Psychiatry Clin Neurosci 2009; 259:137-42.

Pae CU, Serretti A, Mandelli L et al. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenet Genomics 2007; 17:69-75.

Pae CU, Serretti A, Mandelli L et al. Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144:701-3.

Paek IB, Kim SY, Kim MS, Kim J, Lee G, Lee HS. Characterization of human liver cytochrome P-450 enzymes involved in the O-demethylation of a new P-glycoprotein inhibitor HM-30181. J Toxicol Environ Health A 2007; 70:1356-64.

Paetzold SC, Ross NW, Richards RC, Jones M, Hellou J, Bard SM. Up-regulation of hepatic ABCC2, ABCG2, CYP1A1 and GST in multixenobiotic-resistant killifish (Fundulus heteroclitus) from the Sydney Tar Ponds, Nova Scotia, Canada. Mar Environ Res 2009; 68:37-47.

Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.

Page RL 2nd, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother 2005; 39:1109-13.

Page RM, Baumann K, Tomioka M et al. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 2008; 283:677-83.

Pagler TA, Wang M, Mondal M et al. Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling. Circ Res 2011; 108:194-200.

Pai AB, Norenberg J, Boyd A, Raj D, Chan LN. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study. Clin Ther 2007; 29:2699-705.

Pai HV, Kommaddi RP, Chinta SJ, Mori T, Boyd MR, Ravindranath V. A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J Biol Chem 2004; 279:27383-9.

Pai JK, Kraft P, Cannuscio CC et al. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 2006; 186:132-9.

Pai TG, Oxendine I, Sugahara T, Suiko M, Sakakibara Y, Liu MC. Structure-function relationships in the stereospecific and manganese-dependent 3,4-dihydroxyphenylalanine/tyrosine-sulfating activity of human monoamine-form phenol sulfotransferase, SULT1A3. J Biol Chem 2003; 278:1525-32.

Paik D, Cocco E, Bellone S et al. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol Oncol 2010; 119:140-5.

Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 2004; 32:1146-53.

Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 2005; 312:1151-60.

Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 2006; 34:880-6.

Paine MF, Leung LY, Lim HK et al. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J Pharmacol Exp Ther 2002; 301:174-86.

Paine MF, Ludington SS, Chen ML, Stewart PW, Huang SM, Watkins PB. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 2005; 33:426-33.

Paine MF, Schmiedlin-Ren P, Watkins PB. Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 1999; 27:360-4.

Paine MF, Shen DD, Kunze KL et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60:14-24.

Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther 2002; 72:524-35.

Paine MF, Widmer WW, Hart HL et al. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 2006; 83:1097-105.

Paine MF, Widmer WW, Pusek SN et al. Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr 2008; 87:863-71.

Painter JN, Nyholt DR, Morris A et al. High-density fine-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19. Fertil Steril 2011; 95:2236-40.

Paiva L, Marcos R, Creus A, Coggan M, Oakley AJ, Board PG. Polymorphism of glutathione transferase Omega 1 in a population exposed to a high environmental arsenic burden. Pharmacogenet Genomics 2008; 18:1-10.

Pajic M, Murray J, Marshall GM, Cole SP, Norris MD, Haber M. ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. Pharmacogenet Genomics 2011; 21:270-9.

Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003; 3:207-13.

Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S et al. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol 2007; 8:609-11.

Pakaski M, Rakonczay Z, Kasa P. Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro. Neurochem Int 2001; 38:219-26.

Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006; 1:323-39.

Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006; 78:2131-45.

Pal P, Mihanović M, Molnar S et al. Association of tagging single nucleotide polymorphisms on 8 candidate genes in dopaminergic pathway with schizophrenia in Croatian population. Croat Med J 2009; 50:361-9.

Palacio L, Falla D, Tobon I et al. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a Hispanic population Isolate. Clin Appl Thromb Hemost 2010; 16:83-90.

Palamanda JR, Casciano CN, Norton LA et al. Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine. Drug Metab Dispos 2001; 29:863-7.

Palanisamy N, Manian S. Protective effects of Asparagus racemosus on oxidative damage in isoniazid-induced hepatotoxic rats: an in vivo study. Toxicol Ind Health 2011. doi:10. 1177/0748233711410911.

Palatini P, Ceolotto G, Ragazzo F et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 2009; 27:1594-601.

Palazzolo I, Gliozzi A, Rusmini P et al. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol 2008; 108:245-53.

Palmer BR, Jarvis MD, Pilbrow AP et al. Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort. Am Heart J 2008; 156:752-8.

Palmer JS, Duffy DL, Box NF et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66:176-86.

Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002; 165:861-6.

Palmer MS, Drygen AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisponses to sporadic Creutzfeldt-Jakob disease. Nature 1991; 352:340-2.

Palmerini E, Fan K, Yang K et al. Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/- /Apc1638(N/+) mice. Anticancer Res 2007; 27:3807-12.

Palmieri C, Januszewski A, Stanway S, Coombes RC. Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer. Expert Rev Anticancer Ther 2011; 11:179-83.

Palner M, McCormick P, Gillings N, Begtrup M, Wilson AA, Knudsen GM. Radiosynthesis and ex vivo evaluation of (R)-(-)-2-chloro-N-[1-11C-propyl]n-propylnorapomorphine. Nucl Med Biol 2010; 37:35-40.

Palo J, Somer H, Ikonen E, Karila L, Peltonen L. Low prevalence of Huntigton’s disease in Finland. Lancet 1987; 1:805-6.

Palovaara S, Kivistö KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1’-hydroxylation. Br J Clin Pharmacol 2000; 50:333-7.

Palovaara S, Tybring G, Laine K. The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol 2003; 56:232-7.

Palozza P, Simone R, Catalano A, Parrone N, Monego G, Ranelletti FO. Lycopene regulation of cholesterol synthesis and efflux in human macrophages. J Nutr Biochem 2011; 22:971-8.

Pals P, Lincoln S, Manning J et al. alpha-Synuclein promoter confers susceptibility to Parkinson’s disease. Ann Neurol 2004; 56:591-5.

Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011; 5:117-24.

Palli D, Polidoro S, D’Errico M et al. Polymorphic DNA repair and metabolic genes: a multigenic study on gastric cancer. Mutagenesis 2010; 25:569-75.

Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002; 43:1221-8.

Pan G, Giri N, Elmquist WF. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos 2007; 35:1165-73.

Pan G, Winter TN, Roberts JC, Fairbanks CA, Elmquist WF. Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Mol Pharm 2010; 7:138-45.

Pan HJ, Lin Y, Chen YE, Vance DE, Leiter EH. Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. Vascul Pharmacol 2006; 45:65-71.

Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer. Acta Oncol 2007; 46:361-6.

Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008; 75:380-5.

Pan JJ, Shen WW. Serotonin syndrome induced by low-dose venlafaxine. Ann Pharmacother 2003; 37:209-11.

Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 1999; 55:599-604.

Pan L, Vander Stichele R, Rosseel MT, Berlo JA, de Schepper N, Belpaire FM. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther Drug Monit 1999; 21:489-97.

Pan LP, de Vriendt C, Belpaire FM. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 1998; 8:383-9.

Pan LP, Wijnant P, de Vriendt C, Rosseel MT, Belpaire FM. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 1997; 44:557-64.

Pan X, Li Y, Qiu Y et al. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults. Clin Ther 2010; 32:2003-11.

Pan X, Liu Y, Zhang Y, Zhang X, Xu Q, Tong W. Interaction of the C-344T polymorphism of CYP11b2 gene with body mass index and waist circumference affecting diastolic blood pressure in Chinese Mongolian population. Blood Press 2010; 19:373-9.

Pan X, Wang P, Hu N et al. A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans. Drug Metab Pharmacokinet 2011; 26:387-98.

Pan XQ, Liu YY, Wang LF et al. Association of aldosterone synthase (CYP11B2) gene -344T/C polymorphism with essential hypertension in Mongolian nationality. Zhonghua Yu Fang Yi Xue Za Zhi 2010; 44:800-5.

Pan XQ, Zhang YH, Liu YY, Tong WJ. Interaction between the C(-344)T polymorphism of CYP11B2 and alcohol consumption on the risk of essential hypertension in a Chinese Mongolian population. Eur J Epidemiol 2010; 25:813-21.

Pan Y, Abd-Rashid BA, Ismail Z et al. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica. J Ethnopharmacol 2010; 130:275-83.

Pan Y, Abd-Rashid BA, Ismail Z et al. In vitro determination of the effect of Andrographis paniculata extracts and andrographolide on human hepatic cytochrome P450 activities. J Nat Med 2011; 65:440-7.

Pan Y, Abd-Rashid BA, Ismail Z et al. In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19). J Ethnopharmacol 2011; 133:881-7.

Pan Y, Abd-Rashid BA, Ismail Z et al. In vitro effects of active constituents and extracts of Orthosiphon stamineus on the activities of three major human cDNA-expressed cytochrome P450 enzymes. Chem Biol Interact 2011; 190:1-8.

Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009; 37:2112-7.

Pan ZQ, Fang ZQ, Lu WL. Characteristics of gene expression of adrenal cortical steroid synthetase and its regulatory factor in mice with H22 liver cancer of different patterns. Zhongguo Zhong Xi Yi Jie He Za Zhi 2011; 31:85-9.

Panaro MA, Cavallo P, Acquafredda A, Cianciulli A, Calvello R, Mitolo V. Expression of UDP-glucuronosyltransferase 1A6 isoform in Caco-2 cells stimulated with lipopolysaccharide. Innate Immun 2010; 16:302-9.

Panayi AE, Spyrou NM, Iversen BS, White MA, Part P. Determination of cadmium and zinc in Alzheimer’s brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci 2002; 195:1-10.

Panconesi A, Anselmi B, Curradi C, Perfetto F, Piluso A, Franchi G. Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients. Headache 1994; 34:194-7.

Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis 2009; 24:895-905.

Panda D, Samuel JC, Massie M, Feinstein SC, Wilson L. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc Nat Acad Sci USA 2003; 100:9548-53.

Pande M, Amos CI, Eng C, Frazier ML. Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case-only analysis. Mol Carcinog 2010; 49:974-80.

Pander J, Gelderblom H, Antonini NF et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010; 46:1829-34.

Pander J, Gelderblom H, Guchelaar HJ. Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 2007; 12:1054-60.

Pander J, Guchelaar HJ, Gelderblom H. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet. Curr Opin Mol Ther 2010; 12:654-61.

Pandey SC, Carr LG, Heilig M, Ilveskoski E, Thiele TE. Neuropeptide y and alcoholism: genetic, molecular, and pharmacological evidence. Alcohol Clin Exp Res 2003; 27:149-54.

Pandey SC, Piano MR, Pandey GN. Alterations in serotonin1B (5HT1B) receptor subtypes in the brain of ethanol-treated rats. Drug Alcohol Depend 1996; 41:219-25.

Pandit S, Mukherjee PK, Ponnusankar S, Venkatesh M, Srikanth N. Metabolism mediated interaction of α-asarone and Acorus calamus with CYP3A4 and CYP2D6. Fitoterapia 2011; 82:369-74.

Pandit S, Ponnusankar S, Bandyopadhyay A, Ota S, Mukherjee PK. Exploring the possible metabolism mediated interaction of Glycyrrhiza glabra extract with CYP3A4 and CYP2D6. Phytother Res 2011; 25:1429-34.

Pandya A, Xia XJ, Erdenetungalag R et al. Heterogenous point mutations in the mitochondrial tRNA Ser(UCN) precursor coexisting with the A1555G mutation in deaf students from Mongolia. Am J Hum Genet 1999; 65:1803-6.

Panegyres PK. The effects of excitotoxicity on the expression of the amyloid precursor protein gene in the brain and its modulation by neuroprotective agents. J Neural Transm 1998; 105:463-78.

Panegyres PK, Toufexis K, Kakulas BA et al. A new PRNP mutation (G131V) associated with Gerstmann-Straussler-Scheinker disease. Arch Neurol 2001; 58:1899-902.

Panicker V, Saravanan P, Vaidya B et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009; 94:1623-9.

Pankratz VS, Vierkant RA, O’Byrne MM, Ovsyannikova IG, Poland GA. Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol 2010; 11:48.

Panov AV, Gutekunst CA, Leavitt BR et al. Early mitochondrial calcium defects in Huntigton’s disease are a direct effect of polyglutamines. Nat Neurosci 2002; 5:731-6.

Panserat S, Mura C, Gérard N et al. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. Hum Genet 1994; 94:401-6.

Panserat S, Mura C, Gérard N et al. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Pharmacol 1995; 40:361-7.

Panserat S, Sica L, Gérard N, Mathieu H, Jacqz-Aigrain E, Krishnamoorthy R. CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br J Clin Pharmacol 1999; 47:121-4.

Pansoy A, Ahmed S, Valen E, Sandelin A, Matthews J. 3-methylcholanthrene induces differential recruitment of aryl hydrocarbon receptor to human promoters. Toxicol Sci 2010; 117:90-100.

Panza F, Frisardi V, Imbimbo BP et al. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. Immunotherapy 2010; 2:767-82.

Panza F, Seripa D, D’Onofrio G et al. Neuropsychiatric symptoms, endophenotypes, and syndromes in late-onset Alzheimer’s disease: focus on APOE gene. Int J Alzheimers Dis 2011. doi:10. 4061/2011/721457.

Pan-Zhou XR, Cretton-Scott E, Zhou XJ, Yang MX, Lasker JM, Sommadossi JP. Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3’-azido-3’-deoxythymidine (AZT) to 3’-amino-3’-deoxythymidine. Biochem Pharmacol 1998; 55:757-66.

Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005. doi:10. 1371/journal. pmed. 0020017.

Pao WC, Dickson DW, Crook JE, Finch NA, Rademakers R, Graff-Radford NR. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking AlzheimerDisease clinically. Alzheimer Dis Assoc Disord 2011. doi:10. 1097/WAD. 0b013e31820f8f50.

Paolini M, Cantelli-Forti G, Perocco P, Pedulli GF, Abdel-Rahman SZ, Legator MS. Co-carcinogenic effect of beta-carotene. Nature 1999; 398:760-1.

Papadopoulos AI, Ferwerda B, Antoniadou A et al. Association of toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms with increased infection risk in patients with advanced HIV-1 infection. Clin Infect Dis 2010; 51:242-7.

Papadopoulos N, Nicolaides NC, Wei YF et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263:1625-9.

Papon MA, Whittington RA, El-Khoury NB, Planel E. Alzheimer’s disease and anesthesia. Front Neurosci 2011; 4:272.

Pappas P, Stephanou P, Vasiliou V, Marselos M. Anti-inflammatory agents and inducibility of hepatic drug metabolism. Eur J Drug Metab Pharmacokinet 1998; 23:457-60.

Parada-Bustamante A, Ríos R, Ebensperger M, Lardone MC, Piottante A, Castro A. 46,XX/SRY-negative true hermaphrodite. Fertil Steril 2010; 94:2330. e13-6.

Paramithiotis E, Pinard M, Lawton T et al. A prion protein epitope selective for the pathologically misofolded conformation. Nat Med 2003; 9:893-9.

Parang K, Wiebe LI, Knaus EE. Novel approaches for designing 5’-O-ester prodrugs of 3’-azido-2’, 3’-dideoxythymidine (AZT). Curr Med Chem 2000; 7:995-1039.

Parasrampuria R, Mehvar R. Divergent effects of nitric oxide donors on the biliary efflux transporters in isolated perfused rat livers: nitric oxide-independent inhibition of ABC transporters by sodium nitroprusside. Drug Metab Lett 2011; 5:64-72.

Parathyras J, Gebhardt S, Hillermann-Rebello R, Grobbelaar N, Venter M, Warnich L. A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet 2009; 54:261-5.

Parczewski M, Leszczyszyn-Pynka M, Kaczmarczyk M et al. Sequence variants of chemokine receptor genes and susceptibility to HIV-1 infection. J Appl Genet 2009; 50:159-66.

Parchi P, Zou W, Wang W et al. Genetic influence on the structural variations of the abnormal prion protein. Proc. Nat. Acad. Sci 2000; 97:10168-72.

Pare C, Serre D, Brisson D et al. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. Am J Hum Genet 2007; 80:673-82.

Paré G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010; 363:1704-14.

Paré L, Marcuello E, Altés A et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008; 99:1050-5.

Parimoo B, Mishin VM, Busch CM, Thomas PE. Identification of epitopes on cytochrome P450 3A4/5 recognized by monoclonal antibodies. Arch Biochem Biophys 2003; 414:244-54.

Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R, Parkinson A. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 2009; 37:2045-54.

Paris PL, Kupelian PA, Hall JM et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999; 8:901-5.

Park BL, Park SM, Park JS et al. Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics. BMB Rep 2010; 43:445-9.

Park CM, Cha YS, Youn HJ, Cho CW, Song YS. Amelioration of oxidative stress by dandelion extract through CYP2E1 suppression against acute liver injury induced by carbon tetrachloride in Sprague-Dawley rats. Phytother Res 2010; 24:1347-53.

Park CS, Kang JH, Chung WG et al. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics 2002; 12:77-80.

Park DJ, Lenz HJ. Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol 2006; 6:337-44.

Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61:8654-8.

Park EJ, Cho HY, Lee YB. Effect of cimetidine and phenobarbital on metabolite kinetics of omeprazole in rats. Arch Pharm Res 2005; 28:1196-202.

Park H, Lee S, Suh J. Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome P450 3A4. J Am Chem Soc 2005; 127:13634-42.

Park H, Parker GL, Boardman CH, Morris MM, Smith TJ. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer 2011; 19:859-63.

Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 2007; 81:539-46.

Park HJ, Song KS, Nah BM, Choi JR, Kim MJ. Homozygous type I Protein C deficiency in neonatal purpura fulminans with a novel frame-shift deletion of 10 base pairs in exon 8 of PROC gene. J Thromb Haemost 2005; 3:593-5.

Park HK, Park HW, Jeon SG et al. Distinct association of genetic variations of vascular endothelial growth factor, transforming growth factor-beta, and fibroblast growth factor receptors with atopy and airway hyperresponsiveness. Allergy 2008; 4:447-53.

Park HS, Choi JY, Lee MJ et al. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci 2011; 26:1007-13.

Park HS, Kim Y, Lee C. Single nucleotide variants in the beta2-adrenergic and beta3-adrenergic receptor genes explained 18. 3% of adolescent obesity variation. J Hum Genet 2005; 50:365-9.

Park HW, Shin ES, Lee JE et al. Association between genetic variations in prostaglandin E2 receptor subtype EP3 gene (Ptger3) and asthma in the Korean population. Clin Exp Allergy 2007; 37:1609-15.

Park IH, Kim JY, Jung JI, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 2010; 28:791-9.

Park IH, Lee YS, Lee KS et al. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1615-y.

Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008; 38:1240-51.

Park JK, Hong IH, Ki MR et al. Vitamin C deficiency increases the binucleation of hepatocytes in SMP30 knock-out mice. J Gastroenterol Hepatol 2010; 25:1769-76.

Park JK, Kim W, Kim SW, Koh GY, Park SK. Gene-polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with erectile dysfunction. Int J Impot Res 1999; 11:273-6.

Park JM, Lin YS, Calamia JC et al. Transiently altered acetaminophen metabolism after liver transplantation. Clin Pharmacol Ther 2003; 73:545-53.

Park JR, Kim RJ, Lee YK et al. Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells. J Hepatol 2011; 54:122-31.

Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010; 177:1087-94.

Park JY, Kim KA. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. Eur J Clin Pharmacol 2003; 59:407-9.

Park JY, Kim KA, Kim SL. Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother 2003; 47:3464-9.

Park JY, Shon JH, Kim KA et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol 2006; 26:135-42.

Park KS, Baek JA, Do JE, Bang D, Lee ES. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet’s disease. Tissue Antigens 2009; 74:222-7.

Park KW, Park JJ, Jeon KH et al. Enhanced clopidogrel responsiveness in smokers: smokers’ paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011; 31:665-71.

Park KW, Park JJ, Lee SP et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart 2011; 97:641-7.

Park L, Nigg JT, Waldman ID et al. Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol Psychiatry 2005; 10:572-80.

Park M, Han J, Ko JJ et al. Maternal exposure to fenarimol promotes reproductive performance in mouse offspring. Toxicol Lett 2011; 205:241-9.

Park PG, Lee H. Development of thymic lymphomas in mice disrupted of Brca2 allele in the thymus. Exp Mol Med 2008; 40:339-44.

Park PW, Seo YH, Ahn JY, Kim KA, Park JY. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009; 34:569-74.

Park S, Kim AJ, Lee M. Synergic effects of alpha-tocopherol and beta-carotene on tert-butylhydroperoxide-induced HepG2 cell injury. Toxicol Ind Health 2009; 25:311-20.

Park SE, Flanagan SE, Hussain K, Ellard S, Shin CH, Yang SW. Characterization of ABCC8 and KCNJ11 gene mutations and phenotypes in Korean patients with congenital hyperinsulinism. Eur J Endocrinol 2011; 164:919-26.

Park SE, Kang ES, Kim Dhet al. Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med 2009; 26:577-81.

Park SH, Kim JH, Bae SS et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation. Biochem Biophys Res Commun 2011; 408:602-8.

Park SJ, Bijangi-Vishehsaraei K, Safa AR. Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells. Int J Biochem Mol Biol 2010; 1:90-100.

Park SR, Kong SY, Nam BH et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer 2011; 104:1126-34.

Park SR, Kong SY, Rhee J et al. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann Oncol 2011; 22:890-6.

Park SW, Ban JY, Yoon KL et al. Involvement of tryptophan hydroxylase 2 (TPH2) gene polymorphisms in susceptibility to coronary artery lesions in Korean children with Kawasaki disease. Eur J Pediatr 2010; 169:457-61.

Park SW, Heo DS, Sung MW. The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. Cell Oncol 2011. doi:10. 1007/s13402-011-0051-7.

Park SW, Lee JG, Kong BG et al. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin Neurosci 2009; 63:433-9.

Park WB, Choe PG, Song KH et al. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis 2010; 51:101-6.

Park WH, Pak YK. Insulin-dependent suppression of cholesterol 7α-hydroxlase is a possible link between glucose and cholesterol metabolisms. Exp Mol Med 2011; 43:571-9.

Park WS, Dong SM, Kim SY et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 1999; 59:307-10.

Park YH, Kim JB. An atypical phenotype of hypokalemic periodic paralysis caused by a mutation in the sodium channel gene SCN4A. Korean J Pediatr 2010; 53:909-12.

Park YH, Kim JG, Shin YW, Kim SH, Whang KY. Effect of dietary inclusion of Lactobacillus acidophilus ATCC 43121 on cholesterol metabolism in rats. J Microbiol Biotechnol 2007; 17:655-62.

Park YK, Lee JM, Kim do Y et al. Association Between Polymorphism of Tumor Necrosis Factor-alpha Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B. Dig Dis Sci 2010; 55:2043-8.

Parker GB, Brotchie HL, Hyett M. Tolerance to desvenlafaxine in rapid metabolizing depressed patients. Int Clin Psychopharmacol 2011; 26:84-7.

Parker RB, Soberman JE. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol. Pharmacotherapy 2011; 31:630-41.

Parker RB, Yates CR, Laizure SC, Weber KT. P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. J Cardiovasc Pharmacol 2006; 47:55-9.

Parker RS, Sontag TJ, Swanson JE, McCormick CC. Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann N Y Acad Sci 2004; 1031:13-21.

Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Paris BL. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet 2010; 25:16-27.

Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199:193-209.

Parkinson PF, Kannangara TS, Eadie BD, Burgess BL, Wellington CL, Christie BR. Cognition, learning behaviour and hippocampal synaptic plasticity are not disrupted in mice over-expressing the cholesterol transporter ABCG1. Lipids Health Dis 2009; 8:5.

Parkman HP, Jacobs MR, Mishra A et al. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci 2011; 56:115-24.

Parmeggiani F, Costagliola C, Gemmati D et al. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenet Genomics 2007; 17:1039-46.

Parmentier JH, Lavrentyev EN, Falck JR, Capdevila JH, Malik KU. Evaluation of cytochrome P450 4 family as mediator of phospholipase D activation in aortic vascular smooth muscle cells. Life Sci 2005; 77:1015-29.

Parnell JA, Reimer RA. Effect of prebiotic fibre supplementation on hepatic gene expression and serum lipids: a dose-response study in JCR:LA-cp rats. Br J Nutr 2010; 103:1577-84.

Partanen J, Jalava KM, Neuvonen PJ. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 1996; 79:274-6.

Parte P, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 2005; 33:1446-52.

Partida-Pérez M, de la Luz Ayala-Madrigal M, Peregrina-Sandoval J et al. Association of LEP and ADIPOQ common variants with colorectal cancer in Mexican patients. Cancer Biomark 2010; 7:117-21.

Parveen Z, Stockner T, Bentele C et al. Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein. Mol Pharmacol 2011; 79:443-52.

Parving HH, de Zeeuw D, Cooper ME et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008; 19:771-9.

Parys S, Kehraus S, Krick A et al. In vitro chemopreventive potential of fucophlorethols from the brown alga Fucus vesiculosus L. by anti-oxidant activity and inhibition of selected cytochrome P450 enzymes. Phytochemistry 2010; 71:221-9.

Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 2008; 18:921-6.

Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008; 1:19-33.

Pascale E, Purcaro C, Passarelli E et al. Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson’s disease and of L-dopa-induced adverse effects. J Neurol Sci 2009; 276:18-21.

Pascolo L, Fernetti C, Pirulli D, Crovella S, Amoroso A, Tiribelli C. Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun 2003; 303:259-65.

Pascual-García M, Carbó JM, León T et al. Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4. J Immunol 2011; 186:4656-67.

Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000; 58:361-72.

Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 2001; 268:6346-58.

Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003; 1619:243-53.

Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 2000; 58:1441-50.

Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000; 274:707-13.

Pascussi JM, Jounaidi Y, Drocourt L, Domergue J, Balabaud C, Maurel P, Vilarem MJ. Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem Biophys Res Commun 1999; 260:377-81.

Pasche B, Wisinski KB, Sadim M et al. Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs. J Exp Clin Cancer Res 2010; 29:57.

Pasini B, Matyakhina L, Bei T et al. Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. J Clin Endocrinol Metab 2007; 92:3728-32.

Pasqualetti G, Danesi R, del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 2007; 8:49-66.

Pasquier J, Magal P, Boulangé-Lecomte C, Webb G, Le Foll F. Consequences of cell-to-cell P-glycoprotein transfer on acquired multidrug resistance in breast cancer: a cell population dynamics model. Biol Direct 2011; 6:5.

Passamonti L, Fera F, Magariello A et al. Monoamine oxidase-a genetic variations influence brain activity associated with inhibitory control: new insight into the neural correlates of impulsivity. Biol Psychiatry 2006; 59:334-40.

Pastina I, Giovannetti E, Chioni A et al. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 2010; 10:511.

Pastor P, Pastor E, Carnero C et al. Familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene. Ann Neurol 2001; 49:263-7.

Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, Casado FJ. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 2008; 38:972-94.

Patel AD, Gerzanich V, Geng Z, Simard JM. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J Neuropathol Exp Neurol 2010; 69:1177-90.

Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005; 44:175-86.

Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004; 11:262-77.

Patel J, Mitra AK. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics 2001; 2:401-15.

Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer 2008; 59:340-9.

Patel M, Tang BK, Kalow W. (S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7. Pharmacogenetics 1995; 5:43-9.

Patel N, Adewoyin T, Chong NV. Age-related macular degeneration: a perspective on genetic studies. Eye 2008; 22:768-76.

Patel NJ, Zamek-Gliszczynski MJ, Zhang P et al. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol Pharmacol 2003; 64:154-9.

Patel V, Booker M, Kramer M et al. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 2008; 283:35078-85.

Paterson JM, Smith SM, Harmar AJ, Antoni FA. Control of a novel adenylyl cyclase by calcineurin. Biochem Biophys Res Commun 1995; 214:1000-8.

Pathak SM, Musmade P, Dengle S, Karthik A, Bhat K, Udupa N. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation. Eur J Pharm Sci 2010; 41:440-51.

Pathak SM, Udupa N. Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin. Biopharm Drug Dispos 2010; 31:202-14.

Pathan SS, Gottesman RF, Mosley TH, Knopman DS, Sharrett AR, Alonso A. Association of lung function with cognitive decline and dementia: the Atherosclerosis Risk in Communities (ARIC) Study. Eur J Neurol 2011; 18:888-98.

Patino MM, Liu JJ, Glover J et al. Support for the prion hypothesis for inheritance of a phenotypic trait in yeast. Science 1996; 273:622-6.

Patki KC, von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 2003; 31:938-44.

Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer’s disease. Curr Drug Metab 2008; 9:332-5.

Patrignani P, Di Febbo C, Tacconelli S et al. Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenet Genomics 2008; 18:611-20.

Patrignani P, Di Febbo C, Tacconelli S et al. Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. Blood 2006; 107:3572-4.

Patrinos GP, Grosveld FG. Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin 2008; 32:229-36.

Patroneva A, Connolly SM, Fatato P et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008; 36:2484-91.

Pattarachotanant N, Sritharathikhun T, Suttirat S, Tencomnao T. Association of C/T polymorphism in intron 14 of the dopamine transporter gene (rs40184) with major depression in a northeastern Thai population. Genet Mol Res 2010; 9:565-72.

Patterson LH, McKeown SR, Robson T, Gallagher R, Raleigh SM, Orr S. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des 1999; 14:473-86.

Patutina OA, Mironova NL, Popova NA et al. The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer 2010; 10:204.

Paudyal BP. Organophosphorus poisoning. JNMA J Nepal Med Assoc 2008; 47:251-8.

Paul KL, Bhatara VS. Anticholinergic delirium possibly associated with protriptyline and fluoxetine. Ann Pharmacother 1997; 31:1260-1.

Paul S, Pant MC, Parmar D, Verma J. Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer. Indian J Cancer 2011; 48:223-9.

Paula Lima AC, Arriagada C, Toro R et al. Small-molecule aggregation inhibitors reduce excess amyloid in a trisomy 16 mouse cortical cell line. Biol Res 2008; 41:129-36.

Paule B, Castagne V, Picard V et al. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol 2010; 27:1066-72.

Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21:904-13.

Pauli-Magnus C, Lang T, Meier Y et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14:91-102.

Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364:551-7.

Paulose T, Hernández-Ochoa I, Basavarajappa MS, Peretz J, Flaws JA. Increased sensitivity of estrogen receptor alpha overexpressing antral follicles to methoxychlor and its metabolites. Toxicol Sci 2011; 120:447-59.

Paul-Samojedny M, Kowalczyk M, Suchanek R et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia-a case-control study. J Mol Neurosci 2010; 42:112-9.

Paulsson K, Horvat A, Strömbeck B et al. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2008; 47:26-33.

Paulusma CC, Bosma PJ, Zaman GJR et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996; 271:1126-8.

Paulusma CC, de Waart DR, Kunne C, Mok KS, Elferink RP. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J Biol Chem 2009; 284:9947-54.

Paulussen A, Lavrijsen K, Bohets H et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000; 10:415-24.

Paulussen AD, Gilissen RA, Armstrong M et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004; 82:182-8.

Paulzen M, Clement HW, Gründer G. Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol 2008; 11:289-91.

Paus E, Jonzier-Perey M, Cochard N, Eap CB, Baumann P. Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Ther Drug Monit 2004; 26:366-74.

Paushkin SV, Kushnirov VV, Smirnov VN et al. In vitro propagation of the prion-like state of yeast Sup35 protein. Science 1997; 277:381-3.

Pautas E, Moreau C, Gouin-Thibault I et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010; 87:57-64.

Pautus S, Yee SW, Jayne M, Coogan MP, Simons C. Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles. Bioorg Med Chem 2006; 14:3643-53.

Pavanello S, Hoxha M, Dioni L et al. Shortened telomeres in individuals with abuse in alcohol consumption. Int J Cancer 2011; 129:983-92.

Pavek P, Cerveny L, Svecova L et al. Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines. Placenta 2007; 28:1004-11.

Pavek P, Pospechova K, Svecova L et al. Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene. Biochem Pharmacol 2010; 79:277-87.

Pavlikova N, Kortner TM, Arukwe A. Peroxisome proliferator-activated receptors, estrogenic responses and biotransformation system in the liver of salmon exposed to tributyltin and second messenger activator. Aquat Toxicol 2010; 99:176-85.

Pavlov TS, Ilatovskaya DV, Levchenko V, Mattson DL, Roman RJ, Staruschenko A. Effects of cytochrome P450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC). Am J Physiol Renal Physiol 2011; 301:672-81.

Pavone LM, Spina A, Rea S et al. Serotonin transporter gene deficiency is associated with sudden death of newborn mice through activation of TGF-beta(1) signalling. J Mol Cell Cardiol 2009; 47:691-7.

Pawarode A, Shukla S, Minderman H et al. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol 2007; 60:179-88.

Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2009; 10:303-9.

Pawlik A, Kurzawski M, Florczak M, Gawronska Szklarz B, Herczyńska M. IL1beta+3953 exon 5 and IL-2 -330 promoter polymorphisms in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23:159-64.

Pawlikowska L, Tran MN, Achrol AS et al. Polymorphisms in genes involved in inflammatory and angiogenic pathways and the risk of hemorrhagic presentation of brain arteriovenous malformations. Stroke 2004; 35:2294-300.

Pawlowska M, Gajda M, Pyka-Fosciak G et al. The effect of doxycycline on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2011; 62:247-50.

Payami H, Grimslid H, Oken B et al. A prospective study od cognitive health in the ealgerly (Oregon brain aging study): effects of family history and apolipoprotein E genotype. Am J Hum Genet 1997; 60:948-56.

Payami H, Lee N, Zareparsi S et al. Parkinson’s disease, CYP2D6 polymorphism, and age. Neurology 2001; 56:1363-70.

Payami H, Schellenberg GD, Zareparsi S et al. Evidence for association of HLA-A2 allele with onset age of Alzheimer’s disease. Neurology 1997; 49:512-8.

Payami H, Zareparsi S, Montee KR et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in woman. Am J Hum Genet 1996; 58:803-11.

Paz MF, Avila S, Fraga MF et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 2002; 62:4519-24.

Pazik J, Ołdak M, Sitarek E et al. Multidrug resistance-associated protein 2 gene (ABCC2) variant in kidney allograft recipients. Transplant Proc 2009; 41:3009-10.

Pea F, Baccarani U, Tavio M et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 2008; 42:1711-6.

Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40:833-68.

Pearce CL, Near AM, van den Berg DJ et al. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer 2009; 100:412-20.

Pearce RE, Gotschall RR, Kearns GL, Leeder JS. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos 2001; 29:1548-54.

Pearce RE, Leeder JS, Kearns GL. Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos 2006; 34:1035-40.

Pearce RE, Lu W, Wang Y, Uetrecht JP, Correia MA, Leeder JS. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab Dispos 2008; 36:1637-49.

Pearce RE, McIntyre CJ, Madan A et al. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 1996; 331:145-69.

Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277:805-16.

Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos 2005; 33:1819-26.

Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 2002; 30:1170-9.

Pearson ER. Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. Front Biosci 2009; 14:4348-62.

Pearson ER, Boj SF, Steele AM et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 2007. doi:10. 1371/journal. pmed. 0040118.

Pearson ER, Pruhova S, Tack CJ et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia 2005; 48:878-85.

Pearson JT, Hill JJ, Swank J, Isoherranen N, Kunze KL, Atkins WM. Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. Biochemistry 2006; 45:6341-53.

Pearson JT, Wahlstrom JL, Dickmann LJ et al. Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol 2007; 20:1778-86.

Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003; 37:420-32.

Peddareddygari LR, Dutra AV, Levenstien MA, Sen S, Grewal RP. An analysis of methylenetetrahydrofolate reductase and glutathione S-transferase omega-1 genes as modifiers of the cerebral response to ischemia. BMC Neurol 2009; 9:37.

Pedersen RS, Brasch-Andersen C, Sim SC et al. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010; 66:1199-205.

Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 2005; 77:458-67.

Pedroza L, Sauma M, Vasconcelos JM et al. Systemic Lupus Erythematosus: Association with KIR and SLC11A1 polymorphisms, ethnic predisposition and influence in clinical manifestations at onset revealed by ancestry genetic markers in an urban Brazilian population. Lupus 2011; 20:265-73.

Peel AL, Rao RV, Cottrell BA et al. Double-strdended RNA-dependent protein kinase, PKR, binds preferentially to Huntigton’s disease (HD) transcripts and is activated in HD tissue. Hum Molec Genet 2001; 10:1531-8.

Peet CF, Enos T, Nave R, Zech K, Hall M. Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet 2005; 30:275-86.

Peeters RP, van den Beld AW, Attalki H et al. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab 2005; 289:75-81.

Peethambaram P, Fridley BL, Vierkant RA et al. Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome. Int J Mol Epidemiol Genet 2011; 2:185-95.

Pegolo S, Giantin M, Dacasto M, Montesissa C, Capolongo F. Testosterone hydroxylation in bovine liver: enzyme kinetic and inhibition study. Xenobiotica 2010; 40:255-61.

Pegoraro RJ, Chikosi A, Rom L, Roberts C, Moodley J. Methylenetetrahydrofolate reductase gene polymorphisms in black South Africans and the association with preeclampsia. Acta Obstet Gynecol Scand 2004; 83:449-54.

Pei DA, Yan YY, Li L et al. Mineralocorticoid receptor, CYP11B2 mRNA expression, and atrial matrix remodelling in patients with atrial fibrillation. Acta Cardiol 2010; 65:527-33.

Pei Y, Scholey J, Thai K, Suzuki M, Cattran D. Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 1997; 100:814-20.

Peiró AM, Novalbos J, Zapater P et al. Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. Pharmacol Res 2009; 59:62-8.

Pejchal J, Osterreicher J, Kuca K, Jun D, Bajgar J, Kassa J. The influence of acetylcholinesterase reactivators on selected hepatic functions in rats. Basic Clin Pharmacol Toxicol 2008; 103:119-23.

Pekcec A, Schneider EL, Baumgärtner W, Stein VM, Tipold A, Potschka H. Age-dependent decline of blood-brain barrier P-glycoprotein expression in the canine brain. Neurobiol Aging 2011; 32:1477-85.

Peklak-Scott C, Smitherman PK, Townsend AJ, Morrow CS. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008; 7:3247-55.

Pekol T, Daniels JS, Labutti J et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005; 33:771-7.

Pekthong D, Blanchard N, Abadie C et al. Effects of Andrographis paniculata extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monooxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures. Chem Biol Interact 2009; 179:247-55.

Pekthong D, Martin H, Abadie C et al. Differential inhibition of rat and human hepatic cytochrome P450 by Andrographis paniculata extract and andrographolide. J Ethnopharmacol 2008; 115:432-40.

Pelkonen O, Myllynen P, Taavitsainen P et al. Carbamazepine: a ‘blind’ assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 2001; 31:321-43.

Peloso GM, Demissie S, Collins D et al. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. J Lipid Res 2010; 51:3524-32.

Pelletier G. Steroidogenic enzymes in the brain: morphological aspects. Prog Brain Res 2010; 181:193-207.

Pemble SE, Wardle AF, Taylor JB. Glutathione S-transferase class Kappa: characterization by the cloning of rat mitochondrial GST and identification of a human homologue. Biochem J 1996; 319:749-54.

Peng B, Cao L, Wang W et al. Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies. Mutagenesis 2010; 25:41-8.

Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44:879-94.

Peng CC, Pearson JT, Rock DA, Joswig-Jones CA, Jones JP. The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4. Arch Biochem Biophys 2010; 497:68-81.

Peng CW, Liu XL, Liu X, Li Y. Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance. J Transl Med 2010; 8:101.

Peng D, Hiipakka RA, Xie JT et al. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice. Br J Pharmacol 2011; 162:1792-804.

Peng FC, Chaing HH, Tang SH, Chen PC, Lu SC. NADPH-cytochrome P-450 reductase is involved in flunitrazepam reductive metabolism in Hep G2 and Hep 3B cells. J Toxicol Environ Health A 2004; 67:109-24.

Peng FC, Chang CC, Yang CY, Edwards RJ, Doehmer J. Territrems B and C metabolism in human liver microsomes: major role of CYP3A4 and CYP3A5. Toxicology 2006; 218:172-85.

Peng FC, Tseng HY, Tsai JC, Lin C, Doehmer J. Role of human hepatic cytochrome P-450s in territrem A metabolism. J Toxicol Environ Health A 2003; 66:1237-48.

Peng GS, Chen YC, Tsao TP, Wang MF, Yin SJ. Pharmacokinetic and pharmacodynamic basis for partial protection against alcoholism in Asians, heterozygous for the variant ALDH2*2 gene allele. Pharmacogenet Genomics 2007; 17:845-55.

Peng H, Dong Z, Qi J et al. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS One 2009. doi:10. 1371/journal. pone. 0005676.

Peng H, Qi J, Dong Z, Zhang JT. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS One 2010. doi:10. 1371/journal. pone. 0015276.

Peng HC, Chen JR, Chen YL, Yang SC, Yang SS. beta-Carotene exhibits antioxidant and anti-apoptotic properties to prevent ethanol-induced cytotoxicity in isolated rat hepatocytes. Phytother Res 2010; 24 Suppl 2:183-9.

Peng HC, Chen YL, Chen JR et al. Effects of glutamine administration on inflammatory responses in chronic ethanol-fed rats. J Nutr Biochem 2011; 22:282-8.

Peng WX, Li HD, Zhou HH. Mechanism of mono-hydroxylation of daidzein in human liver microsomes. Yao Xue Xue Bao 2004; 39:892-6.

Peng WX, Wang LS, Li HD, Abd El-Aty AM, Chen GL, Zhou HH. Evidence for the involvement of human liver microsomes CYP1A2 in the mono-hydroxylation of daidzein. Clin Chim Acta 2003; 334:77-85.

Penna-Martinez M, Ramos-Lopez E, Stern J et al. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid 2009; 19:623-8.

Pennanen L, Welzl H, D’Adamo P, Nitsch RM, Götz J. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol Dis 2004; 15:500-9.

Penyige A, Poliska S, Csanky E et al. Analyses of association between PPAR gamma and EPHX1 polymorphisms and susceptibility to COPD in a Hungarian cohort, a case-control study. BMC Med Genet 2010; 11:152.

Penzak SR, Acosta EP, Turner M et al. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol 2002; 42:1165-70.

Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs 2002; 2:91-106.

Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 1999; 21:304-9.

Penzak SR, Kabuye G, Mugyenyi P et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8:86-91.

Penzak SR, Robertson SM, Hunt JD et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010; 30:797-805.

Peñas-Lledó EM, Dorado P, Agüera Z et al. CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 78.

Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res 2009; 6:86-96.

Perdigones N, Martín E, Robledo G et al. Study of chromosomal region 5p13. 1 in Crohn’s disease, ulcerative colitis, and rheumatoid arthritis. Hum Immunol 2010; 71:826-8.

Peregud-Pogorzelski J, Tetera-Rudnicka E, Kurzawski M et al. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: The Polish multicenter analysis. Pediatr Blood Cancer 2011; 57:578-82.

Pereira AC, McQuillin A, Puri V et al. Genetic association and sequencing of the insulin-like growth factor 1 gene in bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156:177-87.

Pereira C, Pimentel-Nunes P, Brandão C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol 2010; 22:607-13.

Pereira PL, Magnol L, Sahún I et al. A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum Mol Genet 2009; 18:4756-69.

Pereira RB, Vasquez EC, Stefanon I, Meyrelles SS. Oral P. gingivalis infection alters the vascular reactivity in healthy and spontaneously atherosclerotic mice. Lipids Health Dis 2011; 10:80.

Pereira TV, Nunes AC, Rudnicki M, Yamada Y, Pereira AC, Krieger JE. Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension: a role beyond M235T? Hypertension 2008; 51:778-83.

Perepechaeva M, Kolosova N, Grishanova A. Molecular mechanisms of cold-induced CYP1A activation in rat liver microsomes. J Physiol Biochem 2011. doi:10. 1007/s13105-011-0095-1.

Perera F, Tang WY, Herbstman J et al. Relation of DNA methylation of 5’-CpG island of ACSL3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma. PLoS One 2009. doi:10. 1371/annotation/6a678269-9623-4a13-8b19-4e9431ff3cb6.

Perera FP. Environment and cancer: who are susceptible? Science 1997; 278:1068-73.

Perera MA. The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol 2010; 6:17-28.

Perera MA, Gamazon E, Cavallari LH et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011; 89:408-15.

Perera MA, Thirumaran RK, Cox NJ et al. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J 2009; 9:49-60.

Perera V, Gross AS, Xu H, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol 2011; 63:1161-8.

Peretto I, La Porta E. Gamma-secretase modulation and its promise for Alzheimer’s disease: a medicinal chemistry perspective. Curr Top Med Chem 2008; 8:38-46.

Peretz D, Williamson RA, Kaneto K et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412:739-43.

Peretz H, Rosenberg N, Landau M et al. Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3). Hum Mutat 2006; 27:359-69.

Perez AB, Sierra B, Garcia G et al. Tumor necrosis factor-alpha, transforming growth factor-β1, and interleukin-10 gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol 2010; 71:1135-40.

Perez CA, Chen H, Shyr Y et al. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol 2010; 183:2062-9.

Pérez de los Cobos J, Siñol N, Trujols J et al. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007; 89:190-4.

Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005; 102:2174-9.

Pérez M, Real R, Mendoza G, Merino G, Prieto JG, Álvarez AI. Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones. J Vet Pharmacol Ther 2009; 32:498-502.

Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 2000; 85:3365-9.

Pérez VE, Sánchez-Parra C, Villar SS. Etravirine drug interactions. Enferm Infecc Microbiol Clin 2009; 27 Suppl 2:27-31.

Pérez-Andreu V, Roldán V, Antón AI et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113:4977-9.

Pérez-Castrillón JL, Abad Manteca L, Vega G, del Pino Montes J, de Luis D, Dueñas Laita A. Vitamin D levels and lipid response to atorvastatin. Int J Endocrinol 2010; doi:10. 1155/2010/320721.

Perez-García G, Meneses A. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol Biochem Behav 2005; 81:673-82.

Pérez-Martínez P, Corella D, Shen J et al. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am J Clin Nutr 2009; 89:391-9.

Pérez-Martínez P, López-Miranda J, Cruz-Teno C et al. Adiponectin gene variants are associated with insulin sensitivity in response to dietary fat consumption in Caucasian men. J Nutr 2008; 138:1609-14.

Perfetti X, O’Mathúna B, Pizarro N et al. Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metab Dispos 2009; 37:1448-55.

Pergola C, Werz O. 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat 2010; 20:355-75.

Perini JA, Struchiner CJ, Silva-Assunção E et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 2008; 84:722-8.

Perini JA, Vargens DD, Santana IS et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res 2009; 42:1179-84.

Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 2005; 78:362-9.

Perlis RH. Pharmacogenetic studies of antidepressant response: how far from the clinic? Psychiatr Clin North Am 2007; 30:125-38.

Perlis RH, Adams DH, Fijal B et al. Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry 2010; 71:599-605.

Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67:1110-3.

Perlis RH, Purcell S, Fagerness J et al. Family-based association study of lithium-related and other candidate genes in bipolar disorder. Arch Gen Psychiatry 2008; 65:53-61.

Perlis RH, Purcell S, Fava M et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007; 64:689-97.

Perloff ES, Mason AK, Dehal SS et al. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 2009; 39:99-112.

Perloff MD, Störmer E, von Moltke LL, Greenblatt DJ. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003; 20:1177-83.

Perneczky R, Alexopoulos P, Wagenpfeil S, Bickel H, Kurz A. Head circumference, apolipoprotein E genotype and cognition in the Bavarian School Sisters Study. Eur Psychiatry 2011. doi:10. 1016/j. eurpsy. 2011. 01. 008.

Perrett HF, Barter ZE, Jones BC, Yamazaki H, Tucker GT, Rostami-Hodjegan A. Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metab Dispos 2007; 35:1733-6.

Perrin L, Aninat C, Hamon V et al. Metabolism of phenylahistin enantiomers by cytochromes P450: a possible explanation for their different cytotoxicity. Drug Metab Dispos 2008; 36:2381-92.

Perroud N, Aitchison KJ, Uher R et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 2009; 34:2517-28.

Perroud N, Bondolfi G, Uher R et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011; 12:365-77.

Perruche S, Zhang P, Maruyama T, Bluestone JA, Saas P, Chen W. Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome. J Immunol 2009; 183:953-61.

Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH. Coenzyme A-acetylating enzymes in Alzheimer’s disease: possible cholinergic ‘compartment’ of pyruvate dehydrogenase. Neurosci Lett 1980; 18:105-10.

Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Mol Cancer Ther 2010; 9:3322-9.

Perry RT, Collins JS, Harrell LE, Acton RT, Go RC. Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to aged-matched controls. Am J Med Genet 2001; 105:332-42.

Perry RT, Go RCP, Harrell LE, Acton RT. SSCP analysis and sequencing of the human prion protein gene (PRNP) detects two different 24bp delections in an atypical Alzheimer’s disease family. Am J Med Genet 1995; 60:12-8.

Persad AS, Stedeford T, Tanaka S, Chen L, Banasik M. Parkinson’s disease and CYP2D6 polymorphism in Asian populations: A meta-analysis. Neuroepidemiology 2003; 22:357-61.

Persiani S, Canciani L, Larger P et al. In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate. Drug Metabol Drug Interact 2009; 24:195-209.

Persiani S, D’Amato M, Jakate A et al. Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet 2006; 45:1177-88.

Persico AM, Militerni R, Bravaccio C et al. Adenosine deaminase alleles and autistic disorder: case-control and family-based association studies. Am J Med Genet 2000; 96:784-90.

Persson H, Kvist A, Vallon-Christersson J, Medstrand P, Borg A, Rovira C. The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nat Cell Biol 2009; 11:1268-71.

Persson I, Johansson I, Bergling H et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993; 319:207-11.

Persson J, Hasselström J, Maurset A et al. Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol 2002; 57:869-75.

Persson J, Lindberg K, Gustafsson TP, Eriksson P, Paulsson-Berne G, Lundman P. Low plasma adiponectin concentration is associated with myocardial infarction in young individuals. J Intern Med 2010; 268:194-205.

Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49:1123-41.

Peruffo A, Giacomello M, Montelli S, Corain L, Cozzi B. Expression and localization of aromatase P450AROM, estrogen receptor-α, and estrogen receptor-β in the developing fetal bovine frontal cortex. Gen Comp Endocrinol 2011; 172:211-7.

Perwitasari DA, Wessels JA, van der Straaten RJ et al. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol 2011; 41:1168-76.

Pesce JT, Ramalingam TR, Mentink-Kane MM et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 2009. doi:10. 1371/journal. ppat. 1000371.

Pesonen U. NPY L7P polymorphism and metabolic diseases. Regul Pept 2008; 149:51-5.

Petain A, Kattygnarath D, Azard J et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008; 14:7102-9.

Petchanikow C, Saborio GP, Anderes L et al. Biochemical and structural studies of the prion protein polymorphism. FEBS 2001; 509:451-6.

Peters BJ, Maitland-van der Zee AH, Stricker BH et al. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenet Genomics 2008; 18:631-6.

Peters BJ, Rodin AS, Klungel OH et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 2010; 11:1065-76.

Peters EJ, Slager SL, Jenkins GD et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009; 19:1-10.

Peters EJ, Slager SL, Kraft JB et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008. doi:10. 1371/journal. pone. 0001872.

Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9:879-89.

Peters FT, Dragan CA, Kauffels A et al. Biotechnological synthesis of the designer drug metabolite 4’-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6-a versatile alternative to multistep chemical synthesis. J Anal Toxicol 2009; 33:190-7.

Peters FT, Dragan CA, Wilde DR et al. Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4’-hydroxymethyl-alpha pyrrolidinobutyrophenone. Biochem Pharmacol 2007; 74:511-20.

Peters JU, Hunziker D, Fischer H et al. An aminomethylpyrimidine DPP-IV inhibitor with improved properties. Bioorg Med Chem Lett 2004; 14:3575-8.

Peterschmitt MJ, Burke A, Blankstein L et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol 2011; 51:695-705.

Petersdorf EW, Longton GM, Anasetti C et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 1996; 93:15358-63.

Petersen A, Larsen KE, Behr GG et al. Expanded CAG repeats in exon 1 of the Huntigton’s disease gene stimulates dopamine-mediated striatal neuron autophagy and degeneration. Hum Molec Genet 2001; 10:1243-54.

Petersen DD, Kong AN, Jorge LF, Nebert DW, Arias TD. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama. Pharmacogenetics 1991; 1:136-42.

Petersen DD, McKinney CE, Ikeya K. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 1991; 48:720-5.

Petersen MS, Halling J, Damkier P et al. Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. Toxicol Appl Pharmacol 2007; 224:202-6.

Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352:2379-88.

Peters-Golden M, Sampson AP. Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation. J Allergy Clin Immunol 2003; 111(1 Suppl):37-42.

Peterson MM, Mack JL, Hall PR et al. Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection. Cell Host Microbe 2008; 4:555-66.

Peterson S, Schwarz Y, Li SS et al. CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial. Cancer Epidemiol Biomarkers Prev 2009; 18:3118-25.

Petit F, Gajdos V, Capel L et al. Crigler-Najjar type II syndrome may result from several types and combinations of mutations in the UGT1A1 gene. Clin Genet 2006; 69:525-7.

Petit FM, Gajdos V, Parisot F et al. Paternal isodisomy for chromosome 2 as the cause of Crigler-Najjar type I syndrome. Europ J Hum Genet 2005; 13:278-82.

Petrelli F, Cabiddu M, Ghilardi M, Barni S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? Expert Opin Investig Drugs 2009; 18:1467-77.

Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Vasken Aposhian H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 2000; 163:203-7.

Petrick JS, Jagadish B, Mash EA, Aposhian HV. Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 2001; 14:651-6.

Pétriz J, García-López J. Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 1997; 11:1124-30.

Petroianu GA, Arafat K, Schmitt A, Hasan MY. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol 2005; 25:60-7.

Petroianu GA, Hasan MY, Arafat K, Nurulain SM, Schmitt A. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of tiapride. J Appl Toxicol 2005; 25:562-7.

Petropoulos S, Gibb W, Matthews SG. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation. Brain Res 2010; 1357:9-18.

Petropoulos S, Gibb W, Matthews SG. Effect of glucocorticoids on regulation of placental multidrug resistance phosphoglycoprotein (P-gp) in the mouse. Placenta 2010; 31:803-10.

Petropoulos S, Gibb W, Matthews SG. Breast cancer-resistance protein (BCRP1) in the fetal mouse brain: development and glucocorticoid regulation. Biol Reprod 2011; 84:783-9.

Petrovic D, Peterlin B. Pharmacogenomic considerations of the insertion/deletion gene polymorphism of the angiotensin I-converting enzyme and coronary artery disease. Curr Vasc Pharmacol 2004; 2:271-9.

Petrovic MG, Osredkar J, Saraga-Babić M, Petrovic D. K469E polymorphism of the intracellular adhesion molecule 1 gene is associated with proliferative diabetic retinopathy in Caucasians with type 2 diabetes. Clin Experiment Ophthalmol 2008; 36:468-72.

Petrovic V, Piquette-Miller M. Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats. Drug Metab Dispos 2010; 38:1760-6.

Petrovic V, Wang JH, Piquette-Miller M. Effect of endotoxin on the expression of placental drug transporters and glyburide disposition in pregnant rats. Drug Metab Dispos 2008; 36:1944-50.

Petrovsky N, Quednow BB, Ettinger U et al. Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology 2010; 35:1429-39.

Petrusz P, Jeyaraj DA, Grossman G. Microarray analysis of androgen-regulated gene expression in testis: the use of the androgen-binding protein (ABP)-transgenic mouse as a model. Reprod Biol Endocrinol 2005; 3:70.

Petryshen TL, Middleton FA, Tahl AR et al. Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia. Mol Psychiatry 2005; 10:1074-88, 1057.

Petsalo A, Turpeinen M, Pelkonen O, Tolonen A. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column. J Chromatogr A 2008; 1215:107-15.

Petta S, Cammà C, Scazzone C et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51:1158-67.

Pettersson H, Norlin M, Andersson U et al. Metabolism of a novel side chain modified Delta8(14)-15-ketosterol, a potential cholesterol lowering drug: 28-hydroxylation by CYP27A1. Biochim Biophys Acta 2008; 1781:383-90.

Peyronneau MA, Renaud JP, Truan G, Urban P, Pompon D, Mansuy D. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5. Eur J Biochem 1992; 207:109-16.

Pezzini A, Grassi M, del Zotto E et al. Synergistic affect of apolipoprotein E polymorphisms and cigarrette smoking on risk of ischemic stroke in youg adult. Stroke 2004; 35:438-42.

Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are up-regulated during androgen deprivation in prostate cancer. Mol Med 2011; 17:657-64.

Pfeufer A, Jalilzadeh S, Perz S et al. Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res 2005; 96:693-701.

Pfister M, Labbé L, Lu JF et al. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther 2002; 72:133-41.

Pfrunder A, Gutmann H, Beglinger C, Drewe J. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 2003; 55:59-66.

Pham AN, Wang J, Fang J et al. Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins. Pharm Res 2009; 26:936-45.

Pham MH, Rhinn H, Auzeil N et al. Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice. Drug Metab Lett 2011; 5:73-84.

Pham PA, Hendrix CW, Barditch-Crovo P et al. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antivir Ther 2007; 12:963-9.

Pham PA, la Porte CJ, Lee LS et al. Differential Effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009; 53:4385-92

Phawong C, Ouma C, Tangteerawatana P et al. Haplotypes of IL12B promoter polymorphisms condition susceptibility to severe malaria and functional changes in cytokine levels in Thai adults. Immunogenetics 2010; 62:345-56.

Phelps MA, Lin TS, Johnson AJ et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113:2637-45.

Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 2003; 423:435-9.

Philip I, Plantefeve G, Vuillaumier-Barrot S et al. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation 1999; 99:3096-8.

Philip PA, Ali-Sadat S, Doehmer J et al. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs. Cancer Chemother Pharmacol 1999; 3:59-67.

Philip PA, Kaklamanis L, Ryley N et al. Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. Int J Radiat Oncol Biol Phys 1994; 29:277-83.

Philipp M, Brede ME, Hadamek K, Gessler M, Lohse MJ, Hein L. Placental alpha-2-adrenoceptors control vascular development at the interface between mother and embryo. Nat Genet 2002; 31:311-5.

Phillips CG, Harnett MT, Chen W, Smith SM. Calcium-sensing receptor activation depresses synaptic transmission. J Neurosci 2008; 28:12062-70.

Phillips CM, Goumidi L, Bertrais S et al. Gene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndrome. J Lipid Res 2010; 51:1793-800.

Phillips CM, Goumidi L, Bertrais S et al. Additive effect of polymorphisms in the IL-6, LTA, and TNF-{alpha} genes and plasma fatty acid level modulate risk for the metabolic syndrome and its components. J Clin Endocrinol Metab 2010; 95:1386-94.

Phillips JA 3rd, Cogan JD. Genetic basis of endocrine disease. 6. Molecular basis of familial human growth hormone deficiency. J Clin Endocrinol Metab 1994; 78:11-6.

Phillips KA, Ribi K, Fisher R. Do aromatase inhibitors have adverse effects on cognitive function? Breast Cancer Res 2011; 13:203.

Phimmasone S, Kharasch ED. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. Clin Pharmacol Ther 2001; 70:505-17.

Phipps-Green AJ, Hollis-Moffatt JE, Dalbeth N et al. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets. Hum Mol Genet 2010; 19:4813-9.

Piacentini S, Polimanti R, Moscatelli B et al. Glutathione S-transferase gene polymorphisms and air pollution as interactive risk factors for asthma in a multicentre Italian field study: A preliminary study. Ann Hum Biol 2010; 37:427-39.

Piao YJ, Choi JS. Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. J Pharm Pharmacol 2008; 60:625-9.

Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2006; 7:1989-2001.

Picard C, Fieschi C, Altare F et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002; 70:336-48.

Picard E, Houssier M, Bujold K et al. CD36 plays an important role in the clearance of oxLDL and associated age-dependent sub-retinal deposits. Aging 2010; 2:981-9.

Picard N, Cresteil T, Prémaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004; 26:600-8.

Picard N, Djebli N, Sauvage FL, Marquet P. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos 2007; 35:350-5.

Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 2007; 110:1178-86.

Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology 2001; 61 Suppl 2:73-82.

Piccoli C, Ripoli M, Quarato G et al. Coexistence of mutations in PINK1 and mitochondrial DNA in early onset parkinsonism. J Med Genet 2008; 45:596-602.

Pick A, Klinkhammer W, Wiese M. Specific inhibitors of the breast cancer resistance protein (BCRP). ChemMedChem 2010; 5:1498-505.

Pick A, Müller H, Mayer R et al. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 2011; 19:2090-102.

Pickard BS, Knight HM, Hamilton RS et al. A common variant in the 3’UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorder. Proc Natl Acad Sci USA 2008; 105:14940-5.

Pickard BS, Malloy MP, Christoforou A et al. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 2006; 11:847-57.

Pickard D, Malhotra AK, Rooney W et al. Apolipoprotein E epsilon 4 and clinical phenotype in shcizophrenia. Lancet 1997; 350:930-1.

Pickering MC, de Jorge EG, Martinez-Barricarte R et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007; 204:1249-56.

Pickering-Brown S. The tau gene locus and frontotemporal dementia. Dement Geriart Cogn Disord 2004; 17:258-60.

Pickering-Bown SM, Mann DMA, Bourke JP et al. Apolipoprotein E4 and Alzheimer’s disease pathology in Lewy body disease and in other b-amyloid-forming disease. Lancet 1994; 343:1155.

Pickering-Brown S, Baker M, Yen SH et al. Pick’s disease associated with mutations in the tau gene. Ann Neurol 2000; 48:859-67.

Pichard L, Domergue J, Fourtanier G, Koch P, Schran HF, Maurel P. Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. Biochem Pharmacol 1996; 51:591-8.

Pichard L, Gillet G, Bonfils C, Domergue J, Thénot JP, Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23:1253-62.

Pichard-Garcia L, Hyland R, Baulieu J, Fabre JM, Milton A, Maurel P. Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. Drug Metab Dispos 2000; 28:51-7.

Pichard-Garcia L, Weaver RJ, Eckett N et al. The olivacine derivative s 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture. Drug Metab Dispos 2004; 32:80-8.

Pichika R, Jewett DM, Sherman PS et al. Synthesis and in vivo brain distribution of carbon-11-labeled Δ-opioid receptor agonists. Nucl Med Biol 2010; 37:989-96.

Pidgeon GP, Lysaght J, Krishnamoorthy S et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 2007; 26:503-24.

Pienimäki P, Lampela E, Hakkola J, Arvela P, Raunio H, Vähäkangas K. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 1997; 38:309-16.

Pierce DA, Reeves-Daniel AM. Ranolazine-tacrolimus interaction. Ann Pharmacother 2010; 44:1844-9.

Pieters R, Huismans DR, Loonen AH et al. Adenosine deaminase and purine nucleoside phosphorylase in childhood lymphoblastic leukemia: relation with differentiation stage, in vitro drug resistance and clinical prognosis. Leukemia 1992; 6:375-80.

Pietrini V, Puoti G, Limido L et al. Creutzfeldt-Jakob disease with a novel extra-repeat insertional mutation in the PRNP gene. Neurology 2003; 61:1288-91.

Pihlajamäki J, Rissanen J, Heikkinen S et al. Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997; 17:1039-44.

Pike CJ, Balázs R, Cotman CW. Attenuation of beta-amyloid neurotoxicity in vitro by potassium-induced depolarization. J Neurochem 1996; 67:1774-7.

Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol 2009; 30:239-58.

Pike KE, Ellis KA, Villemagne VL et al. Cognition and beta-amyloid in preclinical Alzheimer’s disease: Data from the AIBL study. Neuropsychologia 2011; 49:2384-90.

Pike MG, Mays DC, Macomber DW, Lipsky JJ. Metabolism of a disulfiram metabolite, S-methyl N,N-diethyldithiocarbamate, by flavin monooxygenase in human renal microsomes. Drug Metab Dispos 2001; 29:127-32.

Pikuleva IA. Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos 2006; 34:513-20.

Pikuleva IA. Cytochrome P450s and cholesterol homeostasis. Pharmacol Ther 2006; 112:761-73.

Pikuleva IA, Mast N, Liao WL, Turko IV. Studies of membrane topology of mitochondrial cholesterol hydroxylases CYPs 27A1 and 11A1. Lipids 2008; 43:1127-32.

Pilch DS, Xu Z, Sun Q, LaVoie EJ, Liu LF, Breslauer KJ. A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning. Proc Natl Acad Sci USA 1997; 94:13565-70.

Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 2011; 18:1203-11.

Pilotto A, Seripa D, Franceschi M et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133:465-71.

Pillai L, Levy RM, Yimam M, Zhao Y, Jia Q, Burnett BP. Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Adv Ther 2010; 27:400-11.

Pillai MM, Hayes B, Torok-Storb B. Inducible transgenes under the control of the hCD68 promoter identifies mouse macrophages with a distribution that differs from the F4/80 – and CSF-1R-expressing populations. Exp Hematol 2009; 37:1387-92.

Pillai SG, Kong X, Edwards LD et al. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182:1498-505.

Pillai U, Muzaffar J, Sen S, Yancey A. Grapefruit juice and verapamil: a toxic cocktail. South Med J 2009; 102:308-9.

Pillot GA, Read WL, Hennenfent KL et al. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol 2006; 1:972-8.

Pinheiro SP, Gates MA, Devivo I et al. Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. Int J Mol Epidemiol Genet 2010; 1:320-31.

Pinotti M, Toso R, Girelli D et al. Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies. Blood 2000; 95:3423-8.

Pinsonneault J, Nielsen CU, Sadée W. Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther 2004; 311:1088-96.

Pintér O, Péczely P, Zsebok S, Zelena D. Seasonal changes in courtship behavior, plasma androgen levels and in hypothalamic aromatase immunoreactivity in male free-living European starlings (Sturnus vulgaris). Gen Comp Endocrinol 2011; 172:151-7.

Pinto AG, Horlander J, Chalasani N et al. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol 2005; 59:440-6.

Pinto AG, Wang YH, Chalasani N et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 2005; 77:178-88.

Pinto D, Pereira D, Portela C, da Silva JL, Lopes C, Medeiros R. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 2005; 335:1173-8.

Pinto LA, Stein RT, Kabesch M. Impact of genetics in childhood asthma. J Pediatr 2008; 84(4 Suppl):68-75.

Pinto-Bazurco Mendieta MA, Negri M, Hu Q et al. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling. Arch Pharm 2008; 341:597-609.

Pinto-Bazurco Mendieta MA, Negri M, Jagusch C et al. Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17. Bioorg Med Chem Lett 2008; 18:267-73.

Pinto-Bazurco Mendieta MA, Negri M, Jagusch C et al. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J Med Chem 2008; 51:5009-18.

Piñeiro R, Maffucci T, Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011; 30:142-52.

Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999; 33:22-6.

Pirinen E, Gylling H, Itkonen P et al. Activated polyamine catabolism leads to low cholesterol levels by enhancing bile acid synthesis. Amino Acids 2010; 38:549-60.

Pirmohamed M, Alfirevic A, Vilar J et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000; 10:705-13.

Pirmohamed M, Kitteringham NR, Quest LJ et al. Genetic polymorphism of cytochrome P4502E1 and risk of alcoholic liver disease in Caucasians. Pharmacogenetics 1995; 5:351-7.

Pirozzi M, Quattrini A, Andolfi G et al. Intramuscular viral delivery of paraplegin rescues peripheral axonopathy in a model of hereditary spastic paraplegia. J Clin Invest 2006; 116:202-8.

Pirulli D, Marangella M, Amoroso A. Primary hyperoxaluria: genotype-phenotype correlation. J Nephrol 2003; 16:297-309.

Piscione F, Iaccarino G, Galasso G et al. Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease. J Am Coll Cardiol 2008; 52:1381-8.

Pischon N, Mäki JM, Weisshaupt P et al. Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype. Calcif Tissue Int 2009; 85:119-26.

Pishas KI, Al-Ejeh F, Zinonos I et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res 2011; 17:494-504.

Pishva H, Mahboob SA, Mehdipour P et al. Fatty acid-binding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects. Nutrition 2010; 26:1117-21.

Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 2001; 284:455-60.

Pitarque M, von Richter O, Rodríguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 2004; 23:258-66.

Pitchakarn P, Ohnuma S, Pintha K, Pompimon W, Ambudkar SV, Limtrakul P. Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance. J Nutr Biochem 2011; doi:10. 1016/j. jnutbio. 2010. 11. 005.

Pithavala YK, Tong W, Mount J et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 2010. doi:10. 1007/s10637-010-9511-6.

Pithavala YK, Tortorici M, Toh M et al. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010; 65:563-70.

Piton A, Rauch C, Langouet S, Guillouzo A, Morel F. Involvement of pregnane X receptor in the regulation of CYP2B6 gene expression by oltipraz in human hepatocytes. Toxicol In Vitro 2010; 24:452-9.

Pitsi D, Octave JN. Presenilin 1 stabilizes the C-terminal fragment of the amyloid precursor protein independently of gamma-secretase activity. J Biol Chem 2004; 279:25333-8.

Pituch-Noworolska A, Zaremba M, Wieczorek A. Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. Pol J Pathol 2009; 60:168-73.

Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001; 125:83-91.

Piver B, Berthou F, Dreano Y, Lucas D. Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci 2003; 73:1199-213.

Placzek MR, Misbahuddin A, Chaudhuri KR, Wood NW, Bhatia KP, Warner TT. Cervical dystonia is associated with a polymorphism in the dopamine (D5) receptor gene. J Neurol Neurosurg Psychiatry 2001; 71:262-4.

Planck T, Parikh H, Brorson H et al. Gene expression in graves’ ophthalmopathy and arm lymphedema: similarities and differences. Thyroid 2011; 21:663-74.

Plant NJ, Gibson GG. Evaluation of the toxicological relevance of CYP3A4 induction. Curr Opin Drug Discov Devel 2003; 6:50-6.

Plasschaert SL, Groninger E, Boezen M et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004; 76:220-9.

Plat AW, Stoffers HE, de Leeuw PW et al. The influence of six cardiovascular polymorphisms on a first event of ischemic heart disease is modified by sex and age. Coron Artery Dis 2009; 20:499-505.

Plat AW, Stoffers HE, Klungel OH et al. The contribution of six polymorphisms to cardiovascular risk in a Dutch high-risk primary care population: the HIPPOCRATES project. J Hum Hypertens 2009; 23:659-67.

Platt KL, Edenharder R, Aderhold S, Muckel E, Glatt H. Fruits and vegetables protect against the genotoxicity of heterocyclic aromatic amines activated by human xenobiotic-metabolizing enzymes expressed in immortal mammalian cells. Mutat Res 2010; 703:90-8.

Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 2006; 281:25457-65.

Platts SH, Shi SJ, Meck JV. Akathisia with combined use of midodrine and promethazine. JAMA 2006; 295:2000-1.

Playtakis A, Viskadouraki AK, Tzagournissakis M et al. Increased incidence of sporadic Creudtzfeldt-Jakob disease on the island of Crete associated with a high rate of PRNP 129-methionine homozygosity in the local population. Ann Neurol 2001; 50:227-33.

Plesnicar BK, Zalar B, Breskvar K, Dolzan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 2006; 20:829-33.

Plewka A, Madej P, Plewka D et al. The TRAF2 and TRAF6 expression in myomas and myometrium of women in reproduction and perimenopausal age. Folia Histochem Cytobiol 2010; 48:407-16.

Plomp AS, Florijn RJ, Ten Brink J et al. ABCC6 mutations in pseudoxanthoma elasticum: an update including eight novel ones. Mol Vis 2008; 14:118-24.

Plosker GL, Figgitt DP. Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics 2004; 22:389-411.

Plosker GL, Scott LJ. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs 2003; 63:1299-324.

Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12:928-32.

Pocchiari M, Salvatore M, Cutruzzola F et al. A new point mutation of the prion protein gene in Creutzfeldt-Jakob disease. Ann Neurol 1993; 34:802-7.

Podoly E, Shalev DE, Shenhar-Tsarfaty S et al. The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem 2009; 284:17170-9.

Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol 2010; 29:629-37.

Poduri A, Khullar M, Bahl A, Sharma YP, Talwar KK. A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians. DNA Cell Biol 2009; 28:451-60.

Poelzing S, Forleo C, Samodell M et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation 2006; 114:368-76.

Poggi JC, Barissa GR, Donadi EA et al. Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol 2006; 46:1328-36.

Pohjalainen T, Rinne JO, Någren K et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3:256-60.

Pohjanvirta R. Transgenic mouse lines expressing rat AH receptor variants-a new animal model for research on AH receptor function and dioxin toxicity mechanisms. Toxicol Appl Pharmacol 2009; 236:166-82.

Pohl HR, Scinicariello F. The impact of CYP2E1 genetic variability on risk assessment of VOC mixtures. Regul Toxicol Pharmacol 2011; 59:364-74.

Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurol Sci 1994; 17:525-30.

Poirier J. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer’s disease. J Psychiat Neurosci 1999; 24:147-53.

Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer’s disease. Trends Mol Med 2003; 9:94-101.

Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993; 342:697-9.

Poirier J, Delisle M-C, Quirion R et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92:12260-4.

Poirier O, Georges JL, Ricard S et al. New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: the ECTIM study. Etude Cas-Témoin de l’Infarctus du Myocarde. J Hypertens 1998; 16:1443-7.

Poirier O, Nicaud V, Gariépy J et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness-the ECTIM, AXA, EVA and GENIC Studies. Eur J Hum Genet 2004; 12:213-9.

Pojoga LH, Adamová Z, Kumar A et al. Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol 2010; 298:1776-88.

Pojoga LH, Romero JR, Yao TM et al. Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II. Endocrinology 2010; 151:1236-46.

Pojoga LH, Williams JS, Yao TM et al. Histone demethylase LSD1 deficiency during high salt diet is associated with enhanced vascular contraction, altered NO-cGMP relaxation pathway, and hypertension. Am J Physiol Heart Circ Physiol 2011. doi:10. 1152/ajpheart. 00513. 2011.

Pokharel S, van Geel PP, Sharma UC et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 2004; 110:3129-35.

Pokharel YR, Kim ND, Han HK, Oh WK, Kang KW. Increased ubiquitination of multidrug resistance 1 by ginsenoside Rd. Nutr Cancer 2010; 62:252-9.

Pola R, Flex A, Ciaburri M et al. Responsiveness to cholinesterase inhibitors in Alzheimer’s disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett 2005; 382:338-41.

Polak M, Cavé H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet J Rare Dis 2007; 2:12.

Polanco TA, Crismale-Gann C, Cohick WS. Alcohol exposure in utero leads to enhanced prepubertal mammary development and alterations in mammary IGF and estradiol systems. Horm Cancer 2011; 2:239-48.

Polanczyk G, Zeni C, Genro JP et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64:218-24.

Polanczyk M, Yellayi S, Zamora A et al. Estrogen receptor-1 (Esr1) and -2 (Esr2) regulate the severity of clinical experimental allergic encephalomyelitis in male mice. Am J Pathol 2004; 164:1915-24.

Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26 Suppl 4:35-40.

Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009; 10:837-52.

Polasek O, Jeroncić I, Mulić R et al. Common variants in SLC17A3 gene affect intra-personal variation in serum uric acid levels in longitudinal time series. Croat Med J 2010; 51:32-9.

Polasek TM, Elliot DJ, Lewis BC, Miners JO. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 2004; 311:996-1007.

Polasek TM, Lin FP, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 2011; 71:727-36.

Polasek TM, Miners JO. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 2006; 62:203-8.

Polasek TM, Miners JO. Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol 2008; 65:87-97.

Polasek TM, Sadagopal JS, Elliot DJ, Miners JO. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol 2010; 66:275-83.

Polena S, Gupta MP, Shaikh H et al. Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4. Proc West Pharmacol Soc 2008; 51:60-2.

Polgar O, Deeken JF, Ediriwickrema LS et al. The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant. Mol Cell Biochem 2009; 322:63-71.

Polgar O, Robey RW, Bates SE. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008; 4:1-15.

Polina ER, Contini V, Hutz MH, Bau CH. The serotonin 2A receptor gene in alcohol dependence and tobacco smoking. Drug Alcohol Depend 2009; 101:128-31.

Polisecki E, Muallem H, Maeda N et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008; 200:109-14.

Polonikov AV, Ivanov VP, Solodilova MA et al. Promoter polymorphism G-50T of a human CYP2J2 epoxygenase gene is associated with common susceptibility to asthma. Chest 2007; 132:120-6.

Polonikov AV, Ivanov VP, Solodilova MA et al. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population. Dis Markers 2008; 24:119-26.

Polonikov AV, Ivanov VP, Solodilova MA, Khoroshaya IV, Kozhuhov MA, Panfilov VI. Promoter polymorphism G-50T of a human CYP2J2 epoxygenase gene is associated with common susceptibility to asthma. Chest 2007; 132:120-6.

Polonikov AV, Ivanov VP, Solodilova MA. Genetic variation of genes for xenobiotic-metabolizing enzymes and risk of bronchial asthma: the importance of gene-gene and gene-environment interactions for disease susceptibility. J Hum Genet 2009; 54:440-9.

Polonikov AV, Yarosh SL, Kokhtenko EV, Starodubova NI, Pakhomov SP, Orlova VS. The functional genotype of glutathione S-transferase T1 gene is strongly associated with increased risk of idiopathic infertility in Russian men. Fertil Steril 2010; 94:1144-7.

Polvikoski T, Sulkava R, Haltia M et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. New Engl J Med 1995; 333:1242-7.

Polyak K, Li Y, Zhu H et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998; 20:291-3.

Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 2009; 29:10741-9.

Polymenidou M, Heppner FL, Pellicioli EC et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci USA 2004; 101 Suppl 2:14670-6.

Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276:2045-7.

Polyzos NP, Fatemi HM, Zavos A et al. Aromatase inhibitors in post-menopausal endometriosis. Reprod Biol Endocrinol 2011; 9:90.

Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy 2009; 29:1386-91.

Pollak MR, Brown EM, Chou YH et al. Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993; 75:1297-303.

Pollard HB, Eidelman O, Jacobson KA, Srivastava M. Pharmacogenomics of cystic fibrosis. Mol Interv 2001; 1:54-63.

Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos 2011; 39:729-35.

Poller B, Wagenaar E, Tang SC, Schinkel AH. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 2011; 8:571-82.

Pollex EK, Anger G, Hutson J, Koren G, Piquette-Miller M. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos 2010; 38:740-4.

Pollock PM, Trent JM. The genetics of cutaneous melanoma. Clin Lab Med 2000; 20:667-90.

Pomara N, Bruno D, Nierenberg JJ et al. TOMM40 poly-T variants and cerebrospinal fluid amyloid beta levels in the elderly. Neurochem Res 2011; 36:1124-8.

Pomatto V, Palermo F, Mosconi G et al. Xenoestrogens elicit a modulation of endocannabinoid system and estrogen receptors in 4NP treated goldfish, Carassius auratus. Gen Comp Endocrinol 2011; 174:30-5.

Ponder KL, Salisbury A, McGonnigal B, Laliberte A, Lester B, Padbury JF. Maternal depression and anxiety are associated with altered gene expression in the human placenta without modification by antidepressant use: Implications for fetal programming. Dev Psychobiol 2011; 53:711-23.

Pondugula SR, Brimer-Cline C, Wu J, Schuetz EG, Tyagi RK, Chen T. A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane x receptor. Drug Metab Dispos 2009; 37:719-30.

Pongstaporn W, Rochanawutanon M, Wilailak S, Linasamita V, Weerakiat S, Petmitr S. Genetic alterations in chromosome 10q24. 3 and glutathione S-transferase omega 2 gene polymorphism in ovarian cancer. J Exp Clin Cancer Res 2006; 25:107-14.

Ponnusankar S, Pandit S, Babu R, Bandyopadhyay A, Mukherjee PK. Cytochrome P450 inhibitory potential of Triphala-a Rasayana from Ayurveda. J Ethnopharmacol 2011; 133:120-5.

Pontes H, de Pinho PG, Fernandes E et al. Metabolic interactions between ethanol and MDMA in primary cultured rat hepatocytes. Toxicology 2010; 270:150-7.

Ponting CP, Hutton M, Nyborg A, Baker M, Jansen K, Golde TE. Identification of a novel family of presenilin homologues. Hum Mol Genet 2002; 11:1037-44.

Poole AJ, Li Y, Kim Y et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006; 314:1467-70.

Poole EM, Bigler J, Whitton J, Sibert JG, Potter JD, Ulrich CM. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2006; 15:502-8.

Poon AH, Tantisira KG, Litonjua AA et al. Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenet Genomics 2008; 18:373-82.

Poon LH, Kang GA, Lee AJ. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother 2010; 44:1080-9.

Poonkuzhali B, Lamba J, Strom S et al. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos 2008; 36:780-95.

Pooranaperundevi M, Sumiyabanu MS, Viswanathan P, Sundarapandiyan R, Anuradha CV. Insulin resistance induced by a high-fructose diet potentiates thioacetamide hepatotoxicity. Singapore Med J 2010; 51:389-98.

Poorkaj P, Bird TD, Wijsman E et al. tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998; 43:815-25.

Poorkaj P, Kas A, D’Souza I et al. A genomic sequence analysis of the mouse and human microtubule-associated protein tau. Mammalian Genome 2001; 12:700-12.

Poorkaj P, Muma NA, Zhukareva V et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol 2002; 52:511-6.

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-703.

Popat RA, van Den Eeden SK, Tanner CM et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. Eur J Neurol 2011; 18:756-65.

Pope CN, Karanth S, Liu J, Yan B. Comparative carboxylesterase activities in infant and adult liver and their in vitro sensitivity to chlorpyrifos oxon. Regul Toxicol Pharmacol 2005; 42:64-9.

Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009; 23 Suppl 2:27-34.

Popov AF, Hinz J, Liakopoulos OJ et al. Influence of angiotensin-I-converting-enzyme insertion/deletion gene polymorphism on perioperative hemodynamics after coronary bypass graft surgery. J Cardiovasc Surg 2008; 49:255-60.

Popovic M, Zaja R, Loncar J, Smital T. A novel ABC transporter: the first insight into zebrafish (Danio rerio) ABCH1. Mar Environ Res 2010; 69 Suppl:11-3.

Popp J, Leucht S, Heres S, Steimer W. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J 2009; 9:71-7.

Porcellini E, Calabrese E, Guerini F et al. The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer’s risk and cognitive deterioration. Neurosci Lett 2007; 416:66-70.

Pörksen S, Laborie LB, Nielsen L et al. Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies. BMC Endocr Disord 2010; 10:16.

Porra V, Ferraro-Peyret C, Durand C et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 2005; 90:3028-35.

Porter KE, Basu A, Hubbard AE et al. Association of genetic variation in cystathionine-beta-synthase and arsenic metabolism. Environ Res 2010; 110:580-7.

Portera-Cailliau C, Hedreen JC, Prince DL, Koliatson VE. Evidence for apoptopic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995; 15:3775-87.

Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J Chromatogr A 2010; 1217:7942-8.

Portolés A, Calvo A, Terleira A et al. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006; 46:1195-203.

Portolés A, Terleira A, Calvo A, Martínez I, Resplandy G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006; 46:1188-94.

Porubsky PR, Battaile KP, Scott EE. Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode. J Biol Chem 2010; 285:22282-90.

Posadas I, Santos P, Blanco A, Muñoz-Fernández M, Ceña V. Acetaminophen induces apoptosis in rat cortical neurons. PLoS One 2010. doi:10. 1371/journal. pone. 0015360.

Post SM, Groenendijk M, van der Hoogt CC et al. Cholesterol 7 alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol. Arterioscler Thromb Vasc Biol 2006; 26:2724-30.

Posthumus M, September AV, Keegan M et al. Genetic risk factors for anterior cruciate ligament ruptures: COL1A1 gene variant. Br J Sports Med 2009; 43:352-6.

Postina R. A closer look at alpha-secretase. Curr Alzheimer Res 2008; 5:179-86.

Postina R. Activation of α-secretase cleavage. J Neurochem 2011. doi:10. 1111/j. 1471-4159. 2011. 07459. x.

Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26:289-93.

Potaczek DP, Undas A, Celinska-Lowenhoff M, Szczeklik A. The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects. Cardiovasc Drugs Ther 2006; 20:229-32.

Potapov AA, Iusupova MM, Tendieva VD, Nikitin AG, Nosikov VV. Clinical and prognostic significance of genetic markers of ApoE gene in traumatic brain injury. Zh Vopr Neirokhir Im N N Burdenko 2010:54-62.

Potega A, Dabrowska E, Niemira M et al. The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome p450s. Drug Metab Dispos 2011; 39:1423-32.

Potkin SG, Basile VS, Jin Y et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003; 8:109-13.

Potocnik U, Glavac D, Dean M. Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet 2008; 183:28-34.

Potschka H, Fedrowitz M, Löscher W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats. Epilepsia 2003; 44:1479-86.

Potschka H, Löscher W. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 2001; 12:2387-9.

Pou J, Rebollo A, Roglans N et al. Ritonavir increases CD36, ABCA1 and CYP27 expression in THP-1 macrophages. Exp Biol Med 2008; 233:1572-82.

Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51:289-95.

Pouns O, Mangas A, Coveñas R, Geffard M. Circulating antibodies directed against “polycyclic aromatic hydrocarbon-like” structures in the sera of cancer patients. Cancer Epidemiol 2009; 33:3-8.

Pourahmad J, Eskandari MR, Daraei B. A comparison of hepatocyte cytotoxic mechanisms for thallium (I) and thallium (III). Environ Toxicol 2010; 25:456-67.

Pourahmad J, Eskandari MR, Nosrati M, Kobarfard F, Khajeamiri AR. Involvement of mitochondrial/lysosomal toxic cross-talk in ecstasy induced liver toxicity under hyperthermic condition. Eur J Pharmacol 2010; 643:162-9.

Pourahmad J, Hosseini MJ, Eskandari MR, Shekarabi SM, Daraei B. Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity. Xenobiotica 2010; 40:763-71.

Pourquier P, Gioffre C, Kohlhagen G et al. Gemcitabine (2’,2’-difluoro-2’-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 2002; 8:2499-504.

Pourquier P, Takebayashi Y, Urasaki Y, Gioffre C, Kohlhagen G, Pommier Y. Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A 2000; 97:1885-90.

Povey AC. Gene-environmental interactions and organophosphate toxicity. Toxicology 2010; 278:294-304.

Powell CL, Bradford BU, Craig CP et al. Mechanism for prevention of alcohol-induced liver injury by dietary methyl donors. Toxicol Sci 2010; 115:131-9.

Powell IJ, Zhou J, Sun Y et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol 2004; 172:1848-52.

Powell NA, Clay EH, Holsworth DD et al. Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. Bioorg Med Chem Lett 2005; 15:4713-6.

Powell SJ, Slynn G, Thomas C, Hopkins B, Briggs I, Graham A. Human bradykinin B2 receptor: nucleotide sequence analysis and assignment to chromosome 14. Genomics 1993; 15:435-8.

Powell SM, Zilz N, Beazer-Barclay Y et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359:235-7.

Powis M, Celius T, Matthews J. Differential ligand-dependent activation and a role for Y322 in aryl hydrocarbon receptor-mediated regulation of gene expression. Biochem Biophys Res Commun 2011; 410:859-65.

Poynter JN, Cooney KA, Bonner JD et al. APC I1307K and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15:468-73.

Pozo ND, Medrano LM, Cénit MC et al. MSH5 is not a genetic predisposing factor for immunoglobulin A deficiency but marks the HLA-DRB1*0102 subgroup carrying susceptibility. Hum Immunol 2010; 71:861-4.

Pozzato G, Franzin F, Moretti M et al. Effects of omeprazole on ethanol metabolism: an in vitro and in vivo rat and human study. Pharmacol Res 1994; 29:47-58.

Pozzi A, Popescu V, Yang S et al. The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem 2010; 285:12840-50.

Prabhu S, Fackett A, Lloyd S et al. Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem Biol Interact 2002; 142:83-97.

Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 2006; 7:264-8.

Prakash C, Johnson KA, Gardner MJ. Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. Drug Metab Dispos 2008; 36:1218-26.

Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 Suppl 1:35-42.

Prakash C, O’Donnell J, Khojasteh-Bakht SC. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride. Drug Metab Dispos 2007; 35:1071-80.

Prakash C, Wang W, O’Connell T, Johnson KA. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance. Drug Metab Dispos 2008; 36:2093-103.

Prakash J, Velpandian T, Pande JN, Gupta SK. Serum rifampicin levels in patients with tuberculosis: Effect of P-Glycoprotein and CYP3A4 blockers on its absorption. Clin Drug Investig 2003; 23:463-72.

Praline J, Blasco H, Vourc’h P et al. APOE ε4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. Eur J Neurol 2011; 18:1046-52.

Prasad JV, Boyer FE, Domagala JM et al. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor. Bioorg Med Chem 1999; 7:2775-800.

Prasad KM, Almasy L, Gur RC et al. RGS4 polymorphisms associated with variability of cognitive performance in a family-based schizophrenia sample. Schizophr Bull 2010; 36:983-90.

Prasad P, Tiwari AK, Kumar KM et al. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med Genet 2006; 7:42.

Prasanthi JR, Huls A, Thomasson S, Thompson A, Schommer E, Ghribi O. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol Neurodegener 2009; 4:1.

Prashanth S, Kumar AA, Madhu B, Rama N, Sagar JV. Pharmacokinetic and pharmacodynamic drug interactions of carbamazepine and glibenclamide in healthy albino Wistar rats. J Pharmacol Pharmacother 2011; 2:7-10.

Prathikanti S, Weinberger DR. Psychiatric genetics-the new era: genetic research and some clinical implications. Br Med Bull 2005; 73-4:107-22.

Pratilas CA, Solit DB. Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials 2007; 2:121-34.

Pratt VM, Zehnbauer B, Wilson JA et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diagn 2010; 12:835-46.

Pratt-Hyatt M, Lin HL, Hollenberg PF. Mechanism-based inactivation of human CYP2E1 by diethyldithocarbamate. Drug Metab Dispos 2010; 38:2286-92.

Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 2009; 18:985-9.

Premont RT, Matsuoka I, Mattei MG, Pouille Y, Defer N, Hanoune J. Identification and characterization of a widely expressed form of adenylyl cyclase. J Biol Chem 1996; 271:13900-7.

Prenkert M, Uggla B, Tidefelt U, Strid H. CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells. Anticancer Res 2010; 30:4157-61.

Prenkert M, Uggla B, Tina E, Tidefelt U, Strid H. Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells. Anticancer Res 2009; 29:4071-6.

Preskorn S, Patroneva A, Silman H et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009; 29:39-43.

Preskorn SH. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J Psychopharmacol 2006; 20:85-94.

Preskorn SH, Greenblatt DJ, Flockhart D et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007; 27:28-34.

Preskorn SH, Harvey AT. Cytochrome P450 enzymes and psychopharmacology. In: Bloom FE, Kupfer DJ. (Eds.). Psychopharmacology: The fourth generation of progress. Raven Press, New York, 1995.

Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008; 14:368-78.

Preskorn SH, Shah R, Neff M, Golbeck AL, Choi J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. J Psychiatr Pract 2007; 13:5-12.

Presle N, Lapicque F, Fournel-Gigleux S, Magdalou J, Netter P. Stereoselective irreversible binding of ketoprofen glucuronides to albumin. Characterization of the site and the mechanism. Drug Metab Dispos 1996; 24:1050-7.

Press RR, Ploeger BA, den Hartigh J et al. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol 2010; 66:579-90.

Prestes AP, Marques FZ, Hutz MH, Roman T, Bau CH. Tobacco smoking and the ADRA2A C-1291G polymorphism. J Neural Transm 2007; 114:1503-6.

Pretorius MM, Gainer JV, van Guilder GP et al. The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Clin Pharmacol Ther 2008; 83:122-9.

Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009; 160:622-8.

Pribová M, Gregorová J, Drsata J. Inhibition of aromatic amino acid decarboxylase by a group of non-steroidal anti-inflammatory drugs. Pharmacol Res 1992; 25:271-7.

Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127:895-903.

Price Evans DA, Salah KA, Mobrad MA, Mitchell WD, Olin M, Eggertsen G. Cerebrotendinous xanthomatosis in a Saudi Arabian family-genotyping and long-term follow-up. Saudi Med J 2007; 28:1113-8.

Price RJ, Giddings AM, Scott MP et al. Effect of Pyrethrins on cytochrome P450 forms in cultured rat and human hepatocytes. Toxicology 2008; 243:84-95.

Price RJ, Scott MP, Giddings AM et al. Effect of butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole on cytochrome P450 forms in cultured human hepatocytes. Xenobiotica 2008; 38:574-86.

Price S, Bordogna W, Braganza R et al. Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 2007; 17:363-9.

Prickett TD, Agrawal NS, Wei X et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009; 41:1127-32.

Prieto-Castelló MJ, Cardona A, Marhuenda D, Roel JM, Corno A. Use of the CYP2E1 genotype and phenotype for the biological monitoring of occupational exposure to styrene. Toxicol Lett 2010; 192:34-9.

Primo-Parmo SL, Lightstone H, La Du BN. Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase. Pharmacogenetics 1997; 7:27-34.

Princen K, Schols D. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev 2005; 16:659-77.

Prins HK, Oort M, Zürcher C, Beckers T. Congenital nonspherocytic hemolytic anemia, associated with glutathione deficiency of the erythrocytes. Hematologic, biochemical and genetic studies. Blood 1966; 27:145-66.

Prinz V, Endres M. The acute (cerebro)vascular effects of statins. Anesth Analg 2009; 109:572-84.

Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28:99-112.

Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999; 9:301-9.

Priou P, Gagnadoux F, Dehé C et al. Drug-induced pneumonitis in a patient treated with venlafaxine and propanolol. Rev Mal Respir 2008; 25:610-3.

Prisant LM. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker. J Clin Pharmacol 2008; 48:225-39.

Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997; 44:199-202.

Pritchard MP, Ossetian R, Li DN et al. A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Arch Biochem Biophys 1997; 345:342-54.

Probst A, Götz J, Wiederhold KH et al. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 2000; 99:469-81.

Probst GD, Bowers S, Sealy JM et al. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Bioorg Med Chem Lett 2010; 20:6034-9.

Procopciuc LM, Sitar-Tăut A, Pop D, Sitar-Tăut DA, Olteanu I, Zdrenghea D. Renin angiotensin system polymorphisms in patients with metabolic syndrome (MetS). Eur J Intern Med 2010; 21:414-8.

Prochazka M, Lillioja S, Tait JF et al. Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians. Diabetes 1993; 42:514-9.

Procházková J, Kozubík A, Machala M, Vondráček J. Differential effects of indirubin and 2,3,7,8-tetrachlorodibenzo-p-dioxin on the aryl hydrocarbon receptor (AhR) signalling in liver progenitor cells. Toxicology 2011; 279:146-54.

Projean D, Baune B, Farinotti R et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 2003; 31:748-54.

Projean D, Morin PE, Tu TM, Ducharme J. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 2003; 33:841-54.

Proks P, Arnold AL, Bruining J et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006; 15:1793-800.

Promrat K, McDermott DH, Gonzalez CM et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124:352-60.

Properzi F, Carulli D, Asher RA et al. Chondroitin 6-sulphate synthesis is up-regulated in injured CNS, induced by injury-related cytokines and enhanced in axon-growth inhibitory glia. Eur J Neurosci 2005; 21:378-90.

Proschowsky HF, Flagstad A, Cirera S, Joergensen CB, Fredholm M. Identification of a mutation in the CHAT gene of Old Danish Pointing Dogs affected with congenital myasthenic syndrome. J Hered 2007; 98:539-43.

Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004; 29:664-73.

Prost F, Thormann W. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 2003; 24:2577-87.

Prost F, Thormann W. Assessment of the stereoselective metabolism of methaqualone in man by capillary electrophoresis. Electrophoresis 2003; 24:2598-607.

Proudnikov D, LaForge KS, Hofflich H et al. Association analysis of polymorphisms in serotonin 1B receptor (HTR1B) gene with heroin addiction: a comparison of molecular and statistically estimated haplotypes. Pharmacogenet Genomics 2006; 16:25-36.

Provenzano C, Marino M, Scuderi F, Evoli A, Bartoccioni E. Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. J Neuroimmunol 2010; 218:102-6.

Provias J, Jeynes B. Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. Curr Alzheimer Res 2011; 8:197-202.

Prowell TM, Blackford AL, Byrne C et al. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res 2011. doi:10. 1158/1940-6207. CAPR-11-0154.

Prows CA, Nick TG, Saldaña SN et al. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol 2009; 19:385-94.

Prud’homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 2010. doi:10. 1371/journal. pone. 0013831.

Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25:1191-9.

Prueksaritanont T, Kuo Y, Tang C et al. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 2006; 34:1546-55.

Prueksaritanont T, Lu P, Gorham L, Sternfeld F, Vyas KP. Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase in hepatic metabolism of L-775,606, a potent 5-HT(1D) receptor agonist. Xenobiotica 2000; 30:47-59.

Prueksaritanont T, Ma B, Tang C et al. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br J Clin Pharmacol 1999; 47:291-8.

Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003; 56:120-4.

Prueksaritanont T, Richards KM, Qiu Y et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 2005; 22:71-8.

Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30:1280-7.

Prueksaritanont T, Vega JM, Rogers JD et al. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 2000; 40:1274-9.

Prueksaritanont T, Zhao JJ, Ma B et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301:1042-51.

Pruitt R, Sasi N, Freeman ML, Sekhar KR. Radiosensitization of cancer cells by hydroxychalcones. Bioorg Med Chem Lett 2010; 20:5997-6000

Prusiner SB. Prions causing degenerative neurological disease. Annu Rev Med 1987; 38:381-98.

Prusiner SB. Molecular biology of prion disease. Science 1991; 252:1515-22.

Prusiner SB. Biology and genetics of prion diseases. Ann Rev Microbiol 1994; 48:655-86.

Prusiner SB. Molecular biology and genetics of prion diseases. Cold Spring Harbor Symp Quant Biol 1996; 61:473-93.

Prusiner SB. Prions. Proc Nat Acad Sci USA 1998; 95:13363-83.

Prusiner SB. An introduction to prion biology. In: Prusiner SB (Ed). Prion biology and diseases. Cold Spring Harbor Laboratory Press, New York, 1999:1-66.

Prusiner SB. Development of the prion concept. In: Prusiner SB (Ed). Prion biology and diseases. Cold Spring Harbor Laboratory Press, New York, 1999:67-112.

Prusiner SB, Peters P, Kaneko K et al. Cell biology of prions. In: Prusiner SB (Ed). Prion biology and diseases. Cold Spring Harbor Laboratory Press, New York, 1999:349-91.

Prusiner SB, Scott MR, DeArmond SJ, Carlson G. Transmission and replication of prions. In: Prusiner SB (Ed). Prion biology and diseases. Cold Spring Harbor Laboratory Press, New York, 1999:147-90.

Pruthi S, Boughey JC, Brandt KR et al. A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations. Mayo Clin Proc 2007; 82:1131-40.

Przekop PR Jr, Tulgan H, Przekop AA, Glantz M. Adverse drug reaction to methotrexate: pharmacogenetic origin. J Am Osteopath Assoc 2006; 106:706-7.

Psaty BM, Smith NL, Lemaitre RN et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285:906-13.

Pucci L, Lucchesi D, Chirulli V et al. Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus. Am J Pharmacogenomics 2003; 3:355-8.

Puccinelli E, Gervasi PG, La Marca M, Beffy P, Longo V. Expression and inducibility by phenobarbital of CYP2C33, CYP2C42, CYP2C49, CYP2B22, and CYP3As in porcine liver, kidney, small intestine, and nasal tissues. Xenobiotica 2010; 40:525-35.

Puckett C, Concannon P, Casey C, Hood L. Genomics structure of the human prion protein gene. Am J Hum Genet 1991; 49:320-9.

Puentes CO, Höcherl P, Kühnle M et al. Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). Bioorg Med Chem Lett 2011; 21:3654-7.

Puga A, Ma C, Marlowe JL. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 2009; 77:713-22.

Puisset F, Chatelut E, Dalenc F et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004; 54:265-72.

Puisset F, Chatelut E, Sparreboom A et al. Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother Pharmacol 2007; 60:305-8.

Pujol JL, Viens P, Rebattu P et al. Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J Thorac Oncol 2006; 1:417-24.

Pulendran B, Miller J, Querec TD et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008; 198:500-7.

Pulido T, Sandoval J, Roquet I et al. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. Eur J Clin Invest 2009; 39 Suppl 2:14-8.

Pulkkinen K, Luomala M, Kuusisto H et al. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 2004; 109:342-7.

Pullinger CR, Hakamata H, Duchateau PN et al. Analysis of hABC1 gene 5-prime end: additional peptide sequence, promoter region, and four polymorphisms. Biochem Biophys Res Commun 2000; 271:451-5.

Pumsalid K, Thaisuchat H, Loetchutinat C, Nuntasaen N, Meepowpan P, Pompimon W. A new azafluorenone from the roots of Polyalthia cerasoides and its biological activity. Nat Prod Commun 2010; 5:1931-4.

Punga AR, Stålberg E. Acetylcholinesterase inhibitors in MG: to be or not to be? Muscle Nerve 2009; 39:724-8.

Puntarulo S, Cederbaum AI. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic Biol Med 1998; 24:1324-30.

Punvittayagul C, Wongpoomchai R, Taya S, Pompimon W. Effect of pinocembrin isolated from Boesenbergia pandurata on xenobiotic-metabolizing enzymes in rat liver. Drug Metab Lett 2011; 5:1-5.

Puozzo C, Lens S, Reh C et al. Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005; 44:977-88.

Purdue MP, Johansson M, Zelenika D et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13. 3. Nat Genet 2011; 43:60-5.

Purdue PE, Lumb MJ, Allsop J, Minatogawa Y, Danpure CJ. A glycine-to-glutamate substitution abolishes alanine:glyoxylate aminotransferase catalytic activity in a subset of patients with primary hyperoxaluria type 1. Genomics 1992; 13:215-8.

Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 2003; 56 Suppl 1:30-6.

Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003; 56 Suppl 1:37-44.

Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56 Suppl 1:51-5.

Purper-Ouakil D, Wohl M, Orejarena S et al. Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet 2008; 147:1425-30.

Pursche S, Schleyer E, von Bonin M et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 2008; 3:198-203.

Pustylnyak VO, Gulyaeva LF, Lyakhovich VV. Induction of cytochrome P4502B: role of regulatory elements and nuclear receptors. Biochemistry 2007; 72:608-17.

Putra AC, Tanimoto K, Arifin M, Antariksa B, Hiyama K. Genetic variations in detoxification enzymes and HIF-1α in Japanese patients with COPD. Clin Respir J 2011. doi:10. 1111/j. 1752-699X. 2011. 00255. x.

Puttabyatappa M, Vandevoort CA, Chaffin CL. hCG-induced down-regulation of PPARγ and liver X receptors promotes periovulatory progesterone synthesis by macaque granulosa cells. Endocrinology 2010; 151:5865-72.

Puyo S, Le Morvan V, Robert J. Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro. Mol Diagn Ther 2008; 12:225-34.